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vABSTRACT
Understanding how the ovary functions in a normal, cyclic pattern is necessary in
order to identify what leads to female sub- and infertility. In order to improve fertility and
reproductive success, it is important to understand how genes are regulated in the ovary.
Peroxisome proliferator-activated receptor  (PPAR) has been detected in the ovary of
several species. Previous studies have found that PPAR is involved in steroidogenesis and
can influence female fertility. However, the genes it regulates in the ovary are not known.
The studies described herein were designed to investigate the role of PPAR in ovarian
function. The effect of PPAR on luteal steroid production and luteal cell survival was
investigated. These experiments demonstrated that PPAR did not play a role in the
production and/or breakdown of progesterone, the main hormone produced by the corpus
luteum. It was also found that the localization of PPAR in the corpus luteum was not due to
the presence of macrophages. However, it was determined that PPAR may play a role in
luteal cell survival by regulating an important gene involved in cell survival. In vitro and in
vivo models were created in which the expression of PPAR was selectively reduced in the
ovary. The in vivo model allowed for identification of candidate genes regulated by PPAR .
Finally, the impact of an environmental agonist of PPAR on follicular estradiol production
was also studied. Genistein has been found to bind to and activate PPAR. Experiments
were performed that suggest that genistein may not affect the basal production of estradiol
but may alter response to gonadotropin stimulation. Collectively, these studies were able to
identify candidate ovarian genes regulated by PPAR and possible role(s) of PPAR in the
ovary. The knowledge of the genes regulated by PPAR will allow researchers to further
investigate how regulation of these genes by PPAR is involved in the functioning of the
ovary.
1CHAPTER 1. GENERAL INTRODUCTION
INTRODUCTION
Understanding how the ovary functions in a normal, cyclic pattern is necessary to
identify what goes awry in cases of female sub- and infertility. There are many genes
involved in regulating the ovarian cycle. One family of transcription factors, the peroxisome
proliferator-activated receptors (PPARs), has been located in the ovary of several species.
Very little is known regarding what genes the PPARs target or how they function in ovarian
tissue.
There are three isotypes of PPARs: , , and . The expression of PPAR and 
remains steady throughout follicular development. PPAR is the only isotype that is
differentially expressed in granulosa cells during the ovarian cycle. The expression of
PPAR is down-regulated in response to the lutenizing hormone (LH) surge, which triggers
ovulation [1, 2]. PPAR is expressed primarily in granulosa cells of developing follicles but
is also located in luteal tissue of the naturally cycling rat [2, 3] and bovine [4, 5]. It has been
reported that female mice with disrupted expression of PPAR were either infertile or
subfertile [6]. These findings indicate that PPAR may play a critical role in ovarian
function and female fertility.
The studies described herein were designed to investigate the role of PPAR in
ovarian function. The effect of PPAR on luteal steroid production was investigated, as well
as a possible role for PPAR in luteal cell survival. In vitro and in vivo models were created
in which the expression of PPAR was selectively reduced in granulosa cells to facilitate
investigating ovarian genes that are regulated by PPAR. Finally, the impact of an
environmental agonist of PPAR, genistein, on follicular estradiol production was studied.
Collectively, these studies were able to identify candidate ovarian genes regulated by PPAR
and possible role(s) of PPAR in the ovary.
2DISSERTATION ORGANIZATION
This dissertation, written by the author, is one of the requirements for a doctoral
degree in Animal Physiology. The dissertation is presented in six chapters. Chapter 2
provides a literature review of ovarian function, and the structure and function of PPAR.
The following chapters describe the experiments performed to investigate the function of
PPAR in the ovary. Chapter 3 specifically discusses the role of PPAR in luteal tissue of
the naturally cycling rat. The process of developing models of reduced expression of PPAR
in the ovary is presented in chapter 4. Chapter 5 details a project that investigated the effects
of genistein, a phytoestrogen and PPAR agonist, on estradiol production by bovine follicles.
The dissertation concludes with a general discussion of the results from these experiments
and the possible roles of PPAR in the ovary.
3CHAPTER 2. LITERATURE REVIEW
The following literature review focuses on an overview of the ovary and ovarian
function. This is followed by discussion of the rat/mouse and bovine ovarian cycles because
these two animal models were utilized in the experiments described in this dissertation.
Following the literature review on the ovary and ovarian cycles, PPAR is discussed because
it was the focus of the experiments described in this dissertation due to its potential to impact
ovarian biology.
THE OVARY
The ovary is comprised of three main regions, the hilus, cortex, and medulla (Figure
2.1 A, B, C). Blood and lymphatic vessels, as well as nerves, enter the ovary at the hilus
(Figure 2.1 A). The majority of those vessels and nerves are housed inside the ovary in the
medulla (Figure 2.1 B). Follicles at different stages of development are located in the cortex
of the ovary (Figure 2.1 C). All follicles contain an oocyte, and depending on the stage of
follicular development, have one or two types of cells capable of producing steroid hormones
- granulosa (Figure 2.1 D) and theca cells (Figure 2.1 E). After ovulation, these two
steroidogenic cell types are transformed into luteal cells through a process referred to as
luteinization (Figure 2.1 F).
The Ovarian Cycle
The ovarian, or estrous cycle, is defined as the interval between periods of sexual
receptivity in the non-pregnant female. The ovarian cycle occurs in a cyclic pattern in the
sexually mature female and is broken up into two phases: the follicular phase and the luteal
phase. The follicular phase is characterized by the final stages of follicular growth, and
ovulation – release of the oocyte. The main hormone associated with the follicular phase,
estradiol, is produced by the developing follicle(s). After ovulation, the luteinization of
follicular cells to form a corpus luteum initiates the luteal phase. The corpus luteum
produces progesterone, a hormone needed for the establishment and maintenance of
4pregnancy. The length of the ovarian cycle varies among species. On average, the ovarian
cycle is 4 or 5 days in rats/mice and 21 days in cattle.
Follicular and Luteal Development
Follicular development occurs in stages. The most immature follicle is a primordial
follicle. A mature follicle is called a Graafian, or preovulatory, follicle. During fetal life,
follicular development begins when primordial germ cells develop into oocytes (reviewed by
[7]). Primordial follicles consist of an oocyte surrounded by a single layer of flattened
epithelial cells (Figure 2.2 A). In most mammals, primordial follicles form either before, or
in the first few days after birth.
The next step in folliculogenesis is the development of primary follicles. In primary
follicles, the oocyte is growing and the single layer of flattened epithelial cells surrounding
the oocyte develops into cuboidal granulosa cells (Figure 2.2 B). The granulosa cells
proliferate and the development of a second layer of granulosa cells results in a secondary
follicle (Figure 2.2 C; reviewed by [8]). The oocyte in a secondary follicle continues to grow
and produces the zona pellucida. The zona pellucida is a glycoprotein-rich substance that
forms a protective coat around the oocyte (reviewed by [8]). Granulosa cells located next to
the zona pellucida extend protoplasmatic processes into the oocyte. These protoplasmatic
processes provide nutrition for the oocyte, which influences oocyte development (reviewed
by [9]). During the secondary stage of follicular development, the stromal cells that surround
the follicle differentiate into theca cells. A basement membrane, referred to as the basal
lamina, separates the theca and granulosa cells. The basal lamina prevents blood vessels
from passing into the granulosa cell compartment (reviewed by [8]).
As the follicles continue to grow, an antrum, or fluid filled cavity develops. Follicles
are referred to as antral follicles once this antrum forms. The antrum contains fluid produced
by the granulosa cells (reviewed by [8]). As the antrum develops, the oocyte becomes
displaced from the center of the follicle and the proliferation of granulosa cells decreases.
5A mound, or hillock of granulosa cells, connects the oocyte to the follicle wall; these
granulosa cells are referred to as cumulus cells. The oocyte and cumulus cells together
comprise the cumulus oocyte complex. As the production of antral fluid increases, the
follicle increases in size and is referred to as a Graafian follicle (Figure 2.2 D). The oocyte in
a Graafian follicle has reached its maximum size. At ovulation, the cumulus oocyte complex
is released from the follicle (reviewed by [8]). The follicular phase of the estrous cycle
encompasses the final stages of antral follicular growth, and release of the oocyte at
ovulation.
Not all follicles will develop into Graffian follicles. Most follicles will go through
atresia. Atresia occurs via apoptosis, a highly organized form of cell death, and can occur at
any time during follicular development (reviewed by [10]).
After ovulation, the granulosa and theca cells remaining in the ovary will involute and
form a corpus luteum (reviewed by [11]). The corpus luteum consists of large and small
luteal cells that are derived from the granulosa and theca cells, respectively. These luteal
cells produce progesterone, which is required for the establishment and maintenance of
pregnancy.
Hormones of the Ovarian Cycle
The development of follicles and corpora lutea is controlled by communication
between the hypothalamus, pituitary, and ovary. This relationship between the
hypothalamus, pituitary, and ovary is essential for estradiol production during the follicular
phase, ovulation, and subsequent production of progesterone during the luteal phase.
Hormones produced by the hypothalamus influence the production and release of
hormones from the anterior pituitary, which in turn regulate ovarian hormone production.
One hormone secreted by the hypothalamus, gonadotropin releasing hormone (GnRH),
stimulates the release of the gonadotropins, follicle stimulating hormone (FSH) and
luteinizing hormone (LH), from the anterior pituitary gland (reviewed by [12]). FSH
6stimulates follicles to grow and produce estradiol. LH plays a role in the final stages of
antral follicular development and induces ovulation and formation of the corpus luteum
(reviewed by [12]).
Cooperation between theca and granulosa cells is necessary for the production of
estradiol by the developing follicles. Theca cells contain LH receptors, while granulosa cells
contain FSH receptors. As antral follicles develop, granulosa cells also develop LH
receptors. LH released from the anterior pituitary binds to its receptor on theca cells, which
results in the conversion of cholesterol into progesterone through the actions of the enzymes
P450 side-chain cleavage and 3-hydroxysteroid dehydrogenase (Figure 2.3). Theca cells
also have the enzyme, 17-hydroxylase, which converts progesterone into androgens (Figure
2.3; reviewed by [13]). The androgens produced by the theca cells diffuse across the basal
lamina into granulosa cells. Granulosa cells express the enzyme P450 aromatase, which
converts androgens into estradiol (Figure 2.3; reviewed by [13]). Estradiol from growing
follicles stimulates the hypothalamus to release more GnRH, which results in an increase in
LH and FSH release. The stimulation of GnRH by estradiol occurs in a positive feedback
manner. However, when estradiol levels are low estradiol exerts negative feedback on
GnRH release (discussed below). As the follicle grows, production of estradiol increases.
Once estradiol reaches a threshold level, a large quantity of LH and FSH is released in
response to GnRH. The large quantity of LH and FSH is referred to as the LH surge, due to
the fact that more LH is released than FSH (reviewed by [12]). The LH surge is followed by
ovulation in most species.
After ovulation, the granulosa and theca cells remaining in the ovary become luteal
cells. This transition is termed luteinization (reviewed by [11]). The granulosa cells become
large luteal cells, while the theca cells become small luteal cells. During luteinization, there
is a decrease in estrogen production and an increase in progesterone production (reviewed by
[11]). Both the large and small luteal cells produce progesterone. Large luteal cells also
7produce oxytocin. Oxytocin is also released from the posterior pituitary and both pituitary
and luteal oxytocin are involved in luteal regression (discussed below).
The main role of the corpus luteum is to produce progesterone. The primary target
organs for progesterone are the hypothalamus, uterus, and mammary gland. Progesterone
causes a decrease in hypothalamic release of GnRH. This results in lower LH and FSH
release. The lower production of LH and FSH stimulates low levels of estradiol production.
Low levels of estradiol cause a decrease in GnRH release (negative feedback). Due to the
low levels of GnRH, the levels of LH and estradiol needed for ovulation can not occur, and
therefore, ovulation can not occur.
In order for ovulation to occur, progesterone levels must be low so as not to interfere
with the release of GnRH from the hypothalamus. If a female is not successfully mated then
the corpus luteum will regress, reducing levels of circulating progesterone. There are two
phases to luteal regression. The first is functional luteolysis, which involves a reduction in
progesterone production. Structural luteolysis, regression of the luteal tissue, follows
functional luteolysis (reviewed by [11]).
Luteolysis is believed to occur in response to down-regulation of the progesterone
receptor. The constant high level of progesterone produced by the corpus luteum during the
luteal phase, desensitizes its own receptor. This down-regulation of the progesterone
receptors allows for increased release of GnRH. The increase in GnRH results in the release
of more LH and FSH, and stimulation of follicular cells to produce estradiol [14]. Estradiol
stimulates the hypothalamus and pituitary, and increases GnRH release. This results in
greater estradiol production from growing follicles. Associated with declining progesterone
production during functional luteolysis is a decrease in blood flow to the corpus luteum,
depriving luteal tissue of nutrients and substrates for steroidogenesis. Macrophages and
lymphocytes in the corpus luteum increase during luteolysis and aid in phagocytosis of the
luteal cells.
8THE RODENT (RAT AND MOUSE) ESTROUS CYCLE
Rats/mice are litter-bearing animals. They ovulate multiple follicles and are referred
to as polyovular species. The rat/mouse estrous cycle is 4 or 5 days. There are four phases
of the rat/mouse estrous cycle, each one lasting approximately 24 hours: proestrus, estrus,
metestrus, and diestrus. The follicular phase of the rodent estrous cycle occurs during
proestrus and estrus. Metestrus and diestrus make up the luteal phase.
Prolactin is released from the anterior pituitary and is an important hormone involved
in luteal formation and regression in the rat. It is secreted in low, basal amounts for the
majority of the cycle. Follicular growth and peak estradiol production occur during
proestrous (Figure 2.4 C). Peak estradiol production occurs on the afternoon of proestrus,
which causes an increase in prolactin release (Figure 2.4 B; reviewed by Freeman 1994).
The LH surge occurs on proestrus, in the evening (Figure 2.4 D). Estrus is the time of sexual
receptivity, mating, and ovulation. LH, FSH, and estradiol levels decrease following the LH
surge and remain relatively low through the day of estrus (Figure 2.4 D, E, and C). The
beginning of corpora lutea formation and progesterone production takes place during
metestrus (Figure 2.4 A). By diestrus, luteal progesterone levels have decreased and the
inactive metabolite of progesterone, 20-hydroxyprogesterone, is secreted (reviewed by
[15]). The enzyme, 20-hydroxysteroid dehydrogenase, converts progesterone into 20-
hydroxyprogesterone (reviewed by [15]), and is located in luteal tissue.
Due to the fact that rats/mice ovulate multiple oocytes, they also form several corpora
lutea. These corpora lutea remain in the ovary for 2-3 cycles. Therefore, the cycling
rat/mouse ovary contains new corpora lutea formed from the most recent ovulation, and old
corpora lutea from the past two or three cycles. The newly formed corpora lutea are not
considered fully functional due to the fact that progesterone is produced for only one to two
9days. In order for a rat/mouse to have fully functional corpora lutea, cervical stimulation by
a male or artificial means must take place. Cervical stimulation results in two daily surges of
prolactin, which extends luteal production of progesterone. If the mating results in
pregnancy, corpora lutea will be maintained for 20-22 days. If it is an infertile mating, the
rat/mouse is said to be pseudopregnant, and the corpora lutea will be maintained and produce
progesterone for 12-14 days (reviewed by [16]).
Prolactin not only plays a role in the development of functional corpora lutea, but it is
also involved in luteolysis. An important process in luteal regression is the removal of old
luteal cells by macrophages through the process of phagocytosis. Prolactin has been
associated with increased movement of monocytes and macrophages into the regressing
corpus luteum [17-19]. The surge of prolactin during proestrus initiates luteal regression by
stimulating the migration of macrophages into the corpus luteum. Multiple cycles are needed
for complete luteal demise, because in a non-pregnant rat prolactin is only released once
during the cycle [17].
THE BOVINE ESTROUS CYCLE
The bovine estrous cycle differs from that of the rodent in several ways. First, the
bovine is a monovular species, typically ovulating one oocyte per cycle. Second, the bovine
has a functional luteal phase in which the corpus luteum is formed, produces progesterone,
and regresses if the female is not successfully mated. The third difference is that prolactin
does not appear to be involved in luteal formation or function. The final difference is that
during the luteal phase, two or three waves of follicular development and follicular atresia
occur. The maintenance and/or regression of a single follicle depend on the hormonal
environment and will be discussed below. Only after progesterone levels have decreased due
to luteolysis will a follicle ovulate (reviewed by [11]).
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The estrous cycle in cattle is also divided into four phases, proestrus, estrus, metestrus
and diestrus. Proestrus is the period prior to estrus; estrus is the period of sexual receptivity
and these two phases make up the follicular phase. The periods of metestrus and diestrus
correspond to the luteal phase.
There are five stages of follicular growth during each follicular wave: emergence,
recruitment, selection, dominance, and atresia (Figure 2.5). A follicular wave begins with the
emergence of a cohort of small, antral follicles over one to several days. Recruitment refers
to the time that the continued growth and development of the cohort of follicles requires FSH
(Figure 2.5 R). At the time of recruitment, antral follicles grow from 5 mm to 8 or 9 mm.
The granulosa cells in these antral follicles express mRNA for the FSH receptor, P450 side
chain cleavage, 3-hydroxysteroid dehydrogenase, and P450 aromatase (reviewed by [20]).
Theca cells express mRNA for the LH receptor, P450 side chain cleavage, 17-hydroxylase,
and 3-hydroxysteroid dehydrogenase (reviewed by [21]). Therefore, those follicles
recruited for further growth are producing estradiol. Those follicles not recruited for
continued growth go through atresia.
During follicle selection, one or two follicles from the cohort of recruited growing
follicles is/are chosen for further development, while the rest of the follicles go through
atresia (Figure 2.5 S; reviewed by [22]). At the time of selection, the follicles start producing
the glycoprotein hormone, inhibin. Inhibin suppresses FSH synthesis and release from the
anterior pituitary (reviewed by [23]). The granulosa cells in the selected follicles also
express mRNA for the LH receptor and greater levels of mRNA for 3-hydroxysteroid
dehydrogenase (reviewed by [21]). The expression of LH receptors in the granulosa cells
and an increase in 3-hydroxysteroid dehydrogenase allow for increased estradiol
production. Estradiol enhances aromatase activity, promotes expression of the LH receptor,
and increases sensitivity of granulosa cells to LH and FSH [13]. The beginning of the
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difference in size between selected follicles is referred to as deviation [24]. The first follicle
to acquire LH receptors in its granulosa cells and an increase in 3-hydroxysteroid
dehydrogenase is the follicle that will become dominant, the morphologically larger follicle
that continues to grow and can be ovulated under appropriate hormonal conditions. The
remaining follicle(s), subordinate follicle(s), grows at a slower rate and then regresses
(reviewed by [25, 26]). Early in the follicular wave, the future dominant follicle may be
slightly larger than others in the cohort, since emergence occurs over one to several days.
The earlier emergence gives the dominant follicle a growth advantage over later emerging
follicles, predisposing it to become dominant (reviewed by [23]). The acquisition of LH
receptors in the granulosa cells of the future dominant follicle allows it to be able to grow in
the low FSH environment caused by inhibin release, because it can respond to both LH and
FSH (reviewed by [25]).
If progesterone levels are low, the dominant follicle continues to grow, the granulosa
cells increase expression of mRNA for P450 side chain cleavage, 3-hydroxysteroid
dehydrogenase, and P450 aromatase (reviewed by [23]). Gonadotropin receptors also
increase in granulosa cells. The preovulatory dominant follicle becomes dependent on LH
for continued growth and estradiol synthesis. Androgens are immediately converted to
estradiol in the preovulatory dominant follicle [27]. This increase in estradiol production
stimulates the hypothalamus to release a large quantity of GnRH, and subsequently LH,
resulting in the LH surge which triggers ovulation (Figure 2.5 D). However, if progesterone
levels are high during the follicular wave, such as those characteristic of the luteal phase
discussed previously, ovulation does not occur due to the suppressive effects of progesterone
on GnRH release. The dominant follicle will then go through atresia which results in a
change in the hormonal environment and another follicular wave occurs.
The bovine corpus luteum will be maintained for approximately 16 days before it
regresses (luteolysis). In the bovine, the major luteolytic hormone is prostaglandin F2.
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Prostaglandin F2 is produced by the uterus and its release is stimulated by oxytocin. The
down regulation of the progesterone receptor, as discussed previously, results in increased
estradiol production. Estrogen stimulates the posterior pituitary to release oxytocin and to
increase oxytocin receptors in the uterus. Pituitary oxytocin binds to its receptor in the uterus
and causes low levels of prostaglandin F2 to be released from the uterus. These low levels
of prostaglandin F2 initiate the release of luteal oxytocin. Luteal oxytocin augments the
release of uterine prostaglandin F2. High levels of prostaglandin F2 inhibit progesterone
secretion and cause functional luteolysis (reviewed by [14]). Structural luteolysis follows, as
described previously. After luteolysis, the dominant follicle of the follicular wave can be
ovulated.
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
The peroxisome proliferator-activated receptors (PPARs) are transcription factors that
are members of the nuclear receptor superfamily. The first PPAR was identified in 1990, by
Isseman and Green, and was suggested to play a role in triglyceride and cholesterol
homeostasis [28]. Two other family members were later identified. The initial isotype was
named PPAR, and the other isotypes identified as PPAR and PPAR. The PPARs have
been detected in a wide range of tissues from many species.
The PPARs are ligand-activated transcription factors that control gene expression by
binding to peroxisome proliferator response elements (PPREs) in the promoter region of
target genes (reviewed by [29]). The PPARs form a heterodimer with the retinoid X
receptors (RXR) and bind to the DNA response element (reviewed by [30]).
Four functional domains, characteristic of steroid hormone receptors, have been
identified in all three PPAR isoforms (reviewed by [31]). The A/B domain contains an
activation function element (reviewed by [31]). The C domain is the DNA binding domain
(reviewed by [31]). The D domain is the hinge region and plays a role in receptor
dimerization, as well as serving as a docking site for co-factors (reviewed by [31, 32]). The
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E/F domain contains the ligand-binding domain and is the site of hetero-dimerization
(reviewed by [29]).
The PPARs associate with cofactors that either repress (corepressors) or activate
(coactivators) transcription (Figure 2.6; [29]). Corepressors have histone deacetylase
activity. Silencing mediator for retinoid and thyroid hormone receptors and nuclear receptor
corepressor are two corepressors known to interact with the PPARs (reviewed by [33, 34]).
Coactivators have histone acetylase activity, which causes disruption of the nucleosome.
Two examples of coactivators for the PPARs are cAMP response element binding protein
and steroid receptor coactivator-1. These coactivators allow for chromatin decondensation
near the regulatory region of a gene. A second coactivator complex, vitamin D receptor
interacting protein/thryroid receptor accessory proteins, can then connect the PPAR:RXR
complex to the general transcription factors, which results in initiation of transcription ([35],
reviewed by [29]).
The ability of ligands to bind to the PPARs differs from other nuclear receptors. The
first difference is that activation of the PPARs can occur through a wide range of ligands
(reviewed by [36]). Secondly, ligand recognition between the three isotypes overlaps, with
some ligands binding to one or more of the PPARs with different affinities (reviewed by
[36]). Finally, the PPARs can accommodate several types of ligands, both synthetic and
natural.
There are both endogenous and exogenous ligands for the PPARs. Common
endogenous ligands that bind to the PPARs are eicosanoids and fatty acids (saturated and
unsaturated; [36]). There are also exogenous ligands that activate the PPARs. Certain
phytoestrogens, such as genistein, have been found to bind to and activate PPAR [37, 38].
The thiazolidinediones (TZDs), drugs commonly administered to patients with type II
diabetes, such as rosiglitazone and ciglitazone, are the most notable synthetic compounds that
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can activate PPAR [39]. The clinical use of PPAR ligands warrent investigating the role of
this transcription factor in the ovary, to determine how these therapies may affect female
fertility.
PPAR and Ovarian Biology
All three PPARs have been identified in ovarian tissue. The expression of PPAR
and  remains steady throughout follicular development and the ovarian cycle in the rat,
while the expression of PPAR is differentially expressed during the ovarian cycle (reviewed
by [40]). Therefore, only the role of PPAR in ovarian biology will be discussed.
PPAR has been identified in ovarian tissue from several species, including humans
[41], pigs [42], sheep [43], mice [6], rats [44, 45], cattle [4, 5, 46], zebrafish [47], and
Xenopus laevis [48]. PPAR is expressed primarily in granulosa cells, and is differentially
expressed during the estrous cycle. PPAR is located in granulosa cells of developing
follicles and its expression is inversely related to that of the LH receptor [49]. In both the rat
and sheep, the expression of PPAR in granulosa cells is down-regulated in response to the
LH surge [1, 2]. These results indicate that a decline in PPAR may be needed for ovulation
and/or luteinization to occur.
PPAR has been found to have various effects on ovarian steroid production. Studies
investigating the role of PPAR in granulosa cell steroidogenesis have yielded conflicting
results. Agonists of PPAR stimulated progesterone and estradiol secretion from cultured
granulosa cells from rats [2]. In sheep, progesterone production by granulosa cells was also
stimulated by agonists of PPAR [1]. Aromatase is the enzyme responsible for the
conversion of androgens into estradiol. Komar and Curry (2003) found no correlation
between expression of mRNA for PPAR and that for aromatase, either before or after the
LH surge in Spraque-Dawley rats [49]. However, with a different strain of rat, Lovekamp-
Swan et al. (2003) found that PPAR suppressed aromatase activity in granulosa cells [50].
A decrease in estradiol production due to suppression of aromatase activity was also seen in
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human granulosa–luteal cells [51]. These studies show that PPAR plays a role in ovarian
steroid production; however, its exact role has not been determined.
PPAR has also been detected in luteal tissue. In the rat, luteal tissue from past
ovulations contained greater expression of mRNA for PPAR than luteal tissue from the
most recent ovulation [3]. This is in contrast to the bovine corpus luteum, where PPAR
declines between the early and mid-luteal phase [4]. In bovine luteal tissue, PPAR has been
found to be involved in progesterone production [4]. Lohrke et al. (1998) demonstrated that
two PPAR agonists, ciglitazone and PGJ2, stimulated progesterone production from mid-
phase luteal cells over a 24-hour culture period. Treatment of human granulosa-lutein cells
with PGJ2 had no effect on basal progesterone production, but inhibited LH-stimulated
progesterone production [52]. Taken together, these data suggest that PPAR is an important
player in luteal steroidogenesis.
Studies have determined that PPAR is active in the ovary and that there is
endogenous ligand activity [1, 50, 53]. Sheep and rat granulosa cells were transfected with a
reporter construct driven by PPAR responsive elements [1, 50]. With or without the
addition of an agonist, there was an increase in reporter activity [1, 49, 52]. The increase in
reporter activity without addition of a ligand indicates that there is an endogenous ligand for
PPAR in these cells.
A study by Cui et al. (2002) demonstrated the importance of PPAR in female
fertility [6]. Using cre/loxP technology, Cui et al. (2002) produced a mouse with PPAR
disrupted in the mammary epithelium, B- and T-cells, and the ovary. Cui et al. (2002)
demonstrated that female transgenic mice with the expression of PPAR disrupted in the
ovary are sub- or infertile [6]. Because the expression of PPAR was not disrupted in the
uterus of these transgenic animals, the authors concluded that the lesion causing the sub- and
infertility resided in the ovary.
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Cui et al. (2002) reported that on the day of estrus, circulating concentrations of
progesterone were 50% lower in animals with PPAR disrupted in the ovary compared with
controls. However, the difference was not significant, most likely due to the small sample
size (n=4). Because progesterone from the corpus luteum and estrogen from the ovary are
needed for implantation, it is possible that the sub- and infertility in these mice results from
ovarian dysfunction. This indicates a role for PPAR in proper ovarian function, affecting
female fertility.
Additional evidence supporting a critical role for PPAR in ovarian biology stem
from findings in other systems. For example, PPAR has been found to play a role in
angiogenesis (reviewed in [54]), inflammation, and cell cycle control (reviewed in [29]).
These processes are important in normal ovarian function. Investigating how PPAR
functions in these other processes may indicate the role(s) of PPAR in the ovary. Genes in
the ovary that are involved in angiogenesis, inflammation and cell viability are vascular
endothelial growth factor, cyclooxygenase-2 and bcl-2 respectively. These genes contain a
peroxisome proliferator response elements (PPRE) in their promoter regions [55, 56]. A
PPRE in the promoter region of these genes indicate that PPAR may regulate one or more of
these genes, thereby playing a role in various processes associated with normal ovarian
function.
As stated previously, PPAR is located in ovarian tissue and many studies indicate
that PPAR plays an important role in ovarian function and fertility. The following projects
were performed to determine the role(s) of PPAR in steroidogenesis, and to develop models
of reduced expression of PPAR in the ovary. These models serve as a way to determine
what genes may be regulated by PPAR . Collectively, these studies were able to identify
candidate ovarian genes regulated by PPAR and possible role(s) of PPAR in ovarian
steroid production.
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Figure 2.1. Schematic illustration of the ovary showing the primary
structures and their sequences of development. A) hilus, B) medulla, C) cortex, D)
granulosa cells, E) theca cells, F) corpus luteum. Adapted from Senger 1999.
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Figure 2.2. Schematic representation of the development of the ovarian follicle. A)
primordial follicle, B) primary follicle, C) secondary follicle, D) Graafian follicle. Adapted
from Griffin & Ojeda 2000.
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Figure 2.3. Schematic representation of hormone production in theca and granulosa cells.
The cells of the theca interna contain receptors for LH. Thecal cells produce androgens
(androstenedione or testosterone) through the actions of P450 side chain cleavage, 3-
hydroxsteroid dehydrogenase and 17- hydroxylase. These androgens then diffuse across the basal
lamina into granulosa cells, which contain FSH receptors, and later during development, LH
receptors (see text for details).
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Figure 2.4. Concentrations of progesterone (A), prolactin (B), estradiol (C),
LH (D) and FSH (E) in peripheral plasma throughout each day of the 4-day estrous
cycle of the rat. Adapted from Smith et al., 1975.
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Figure 2.5. Follicular waves during the estrous cycle in cattle. Two or three waves
of growth occur during the estrous cycle. Taken from Senger 1999.
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Figure 2.6. Gene transcription mechanisms of the PPARs. PPARs interacts with
corepressors that inhibit gene transcription. PPARs can also interact with coactivators that
contain histone acetylase activity and facilitate transcription of various genes. Adapted from
Kota et al. 2005.
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CHAPTER 3. POTENTIAL ROLE FOR PEROXISOME
PROLIFERATOR-ACTIVATED RECEPTOR IN
REGULATING LUTEAL LIFESPAN IN THE RAT
A Paper Published in Reproduction1
NS Tinfo2, and CM Komar3
ABSTRACT
Peroxisome proliferator-activated receptor (PPAR ) has been shown to stimulate
progesterone production by bovine luteal cells. We previously reported greater expression of
PPAR in old compared to new luteal tissue in the rat. The following studies were conducted
to determine the role of PPAR in rat corpora lutea (CL) and test the hypothesis that PPAR
plays a role in the metabolism of progesterone and/or luteal lifespan. Ovaries were removed
from naturally cycling rats throughout the estrous cycle, and pseudopregnant rats. Messenger
RNA for PPAR and P-450 side-chain cleavage (SCC) was localized in luteal tissue by in
situ hybridization, and protein corresponding to PPAR and macrophages identified by
immunohistochemistry. Luteal tissue was cultured with agonists (ciglitazone, PGJ2) or an
antagonist (GW-9662) of PPAR . Progesterone was measured in media by RIA and levels of
mRNA for 20-HSD and bcl-2 were measured in luteal tissue after culture by RT-PCR. An
inverse relationship existed between the expression of mRNA for SCC and PPAR . There
was no effect of PPAR agonists or the antagonist on luteal progesterone production in vitro,
or levels of mRNA for 20-HSD. PPAR protein was localized to the nuclei of luteal cells
1 Reprinted with permission of Reproduction, Tinfo &Komar, 2007, 133, 187-96
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2 Primary researcher and author
3 Author for correspondance
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and did not correspond with the presence of macrophages. In new CLs ciglitazone decreased
mRNA for bcl-2 on proestrus, estrus, and metestrus. Interestingly, GW-9662 also decreased
mRNA for bcl-2 on proestrus and diestrus in old and new CLs, and metestrus in new CL.
These data indicate that PPAR is not a major player in luteal progesterone production or
metabolism, but may be involved in regulating luteal lifespan.
INTRODUCTION
The peroxisome proliferator-activated receptors (PPARs) are transcription factors
and members of the nuclear receptor superfamily. There are three isotypes of PPARs:
PPAR, PPAR/, and PPAR. Ovarian tissue from several species, including humans
(Lambe & Tugwood 1996), pigs (Schoppe et al. 2002), sheep (Froment et al. 2003), mice
(Cui et al. 2002), rats (Braissant et al. 1996, Komar et al. 2001) and cattle (Sundvold et al.
1997, Lohrke et al. 1998) express PPAR. Although this transcription factor has been
detected in the ovaries of several species, to date very little is known regarding the role(s)
of PPAR in ovarian function.
Previous work from our laboratory, using the rat as a model, has shown that
PPAR is expressed primarily in granulosa cells and is down-regulated in response to the
LH surge (Komar et al. 2001). PPAR was also identified in luteal tissue of the naturally
cycling rat (Komar & Curry 2002). Interestingly, the expression of mRNA for PPAR
was higher in luteal tissue from previous ovulations compared with luteal tissue forming
from the most recent ovulation (Komar & Curry 2002).
PPAR is involved in processes that are critical to normal ovarian function such as
angiogenesis (Margeli et al. 2003), inflammation, and cell cycle control (Berger & Moller
2002), indicating that PPAR may be an important player regulating ovarian gene
expression. For example, cell death via apoptosis occurs in both ovarian follicles and
corpora lutea (CL). In the ovary, the anti-apoptotic gene, bcl-2, has been found to play a
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role in cell survival. The gene encoding bcl-2 contains a peroxisome proliferator response
element (Butts et al. 2004), and therefore could be directly regulated by PPAR.
Another possible role for PPAR in the ovary may be in the process of luteolysis.
The expression of PPAR is induced during the differentiation of monocytes into
macrophages, and it is expressed in activated macrophages (Ricote et al. 1998, Tontonoz
et al. 1998, Cunard et al. 2002). Macrophages accumulate in regressing CL in the rat
from late proestrus to early estrus (Gaytan et al. 1998). These macrophages are thought to
aid in the removal of luteal tissue by phagocytosis (Niswender et al. 2000). Therefore,
PPAR may play a role in luteolysis via its presence in activated macrophages.
Alternatively, PPAR may be involved in luteal steroid production. In cattle, activation of
PPAR has been reported to stimulate progesterone production by the CL (Lohrke et al.
1998). Luteal tissue collected during the midphase of the bovine estrous cycle and
cultured with an agonist of PPAR, prostaglandin J2 (PGJ2), secreted more progesterone
than control tissue (Lohrke et al. 1998).
The objective of the current study was to determine the role of PPAR in the rat CL.
Given the ability of PPAR agonists to affect progesterone production by bovine luteal cells
coupled with its expression pattern in the rat CL, we hypothesized that PPAR plays a role in
luteal progesterone metabolism. Alternatively, due to its higher expression in old versus new
CL, and the fact that PPAR is expressed in macrophages which play a role in luteolysis, we
also investigated the potential involvement of PPAR in regulating the life cycle of the CL.
Both the naturally cycling and pseudopregnant rat were used as models to assess the impact
of PPAR on progesterone production at various physiological stages. The naturally cycling
rat allowed for investigating the role of PPAR in both newly forming luteal tissue derived
from the most recent ovulation, and regressing luteal tissue present on the ovary from past
ovulations. Because fully functional CL do not develop in cycling rats, the pseudopregnant
rat was used to investigate the role of PPAR in functioning luteal tissue.
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METHODS AND MATERIALS
Animals
All animal procedures were approved by the Iowa State University’s Animal Care
and Use Committee. Adult, female Sprague-Dawley rats were obtained from Harlan
(Indianapolis, IN), and kept on a 14L:10D light:dark cycle. Vaginal smears were taken daily
to monitor the estrous cycle. Animals exhibiting 3 normal estrous cycles were used in the
following experiments.
Ovaries were collected from naturally cycling rats to investigate the relationship
between PPAR and luteal progesterone production. In addition, the association of PPAR
and macrophages in luteal tissue was also investigated to determine if macrophages were the
cells expressing PPAR within the CL. Cycling rats were sacrificed on each day of the
estrous cycle (proestrus, estrus, metestrus, and diestrus), between 09:00 and 10:00 am.
Ovaries were removed, cleaned of adnexa and frozen until processed for in-situ
hybridization, or fixed in 4% paraformaldehyde for immunohistochemical analysis, as
described below. Luteal tissue was also established in culture as described below, to
investigate how agonists and an antagonist of PPAR impact progesterone production and
catabolism.
The expression and function of PPAR was also investigated in luteal tissue from
pseudopregnant rats. Rats were mated with a vasectomized male and sacrificed 10-16 days
later (n=4 animals). Luteal tissue was dissected from one ovary from each animal and
cultured in vitro as described below. The second ovary from each animal was fixed in 4%
paraformaldehyde and embedded in paraffin for immunohistochemical analysis.
In-situ hybridization
Frozen ovarian tissue collected from rats on the days of proestrus, estrus, metestrus,
and diestrus (n= 4 animals/day) were serially sectioned at 10 µM. Consecutive tissue
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sections were used for localization of mRNA for P-450 side-chain cleavage (SCC) and
PPAR. Tissue sections were fixed in 4% paraformaldehyde and dehydrated by passing
through a series of increasing ethanol solutions. Slides were placed in 2 mg/ml glycine in
phosphate buffered saline (PBS; pH=7.2), rinsed in PBS, followed by an incubation in 1.5%
triethanolamine buffer with 0.25% acetic anhydride. Slides were subsequently treated with
2x standard saline citrate (SSC; 0.149 M sodium chloride, 14.9 mM sodium citrate, pH= 7.0)
and dehydrated by passing through a series of decreasing concentrations of ethanol.
Sense and antisense riboprobes for PPAR and SCC (plasmids containing the cDNA
for PPAR and SCC were generously provided by Dr. Walter Walhi, Universite de Lausanne,
Lausanne, Switzerland and Dr. J. S. Richards, Baylor College of Medicine, Houston, TX,
respectively) were synthesized using a MAXISCRIPT kit (Ambion, Inc. Austin, TX) and -
35S-UTP (10 µmCi/ml; ICN Biomedical, Inc., Irvine, CA). Tissues were hybridized with
radiolabeled probe (1 x 106 cpm) in 100 µl hybridization buffer (4 M NaCl, 1 M Tris, 0.5 M
EDTA, 50x Denhardts, 25 mg/ml yeast tRNA, 10 mg/ml polyadenylic acid). After
hybridization, slides were incubated in RNase solution 1 (2x SSC, 50% formamide, 0.1% -
mercaptoethanol), followed by incubation in RNase solution 2 (0.5 M NaCl, 10 mM Tris, 20
µg/ml RNase A). Slides were incubated in RNase solution 1 a second time, after which they
were incubated in 0.1x SSC, 1% -mercaptoethanol. Slides were dehydrated by rinsing with
30% ethanol containing 0.6 M NaCl, 60% ethanol containing 0.6 M NaCl, 80%, 95%, and
100% ethanol. The slides were air dried, dipped in Kodak NTB2 emulsion and exposed at
4°C for 1 week (SCC) or 4 weeks (PPAR ). Slides were developed before being
counterstained with hematoxylin. At least one slide was processed with the sense riboprobe
and two slides with the antisense riboprobe (4 tissue sections/slide) per animal.
Tissue Culture
Luteal tissue from ovaries collected throughout the estrous cycle was dissected from
the ovary using 18 gauge needles. CLs from the current cycle (new) were differentiated from
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CLs from previous cycles (old) by assessing the degree of vascularization (Fig. 3.1). New
CLs were well vascularized, whereas CLs present on the ovary from past cycles were less
vascularized (Bassette 1943). There was no attempt to discern the differences between old
CLs regarding how may cycles they had been present on the ovary. Individual CLs were
hemisected and cultured in 500 µl of defined media (DMEM: F12, 0.01% sodium pyruvate,
0.22% sodium bicarbonate, 1% bovine serum albumin, 0.125% gentamicin, and insulin-
transferrin-sodium selenite media supplement; pH= 7.2). In one experiment, CLs from the
day of estrus (n=5 animals) were cultured in the presence or absence of the PPAR agonists,
ciglitazone (65 µM) or PGJ2 (25 µM). Agents were added at the time tissues were
established in culture and treatments were set up in duplicate. In a second experiment, luteal
tissue from the days of proestrus, estrus, metestrus, and diestrus (n=4 animals/day of the
cycle) were cultured with ciglitazone (65 µM) or the PPAR antagonist GW-9662 (1 µM).
The antagonist, GW-9662 was used because it has previously been shown that there is
endogenous activity of PPAR in the ovary (Froment et al. 2003, Lovekamp-Swan & Chaffin
2005). Luteal tissue from pseudopregnant rats was also cultured with PGJ2 (25 µM) or GW-
9662 (1 µM). Tissues were incubated for 24 hours at 37°C in 5% CO2: 95% air. At the end
of culture, media were collected and stored at -20°C until analyzed by RIA for progesterone.
Tissues were frozen and stored until used for RNA and DNA trizol extraction.
Concentrations of progesterone were corrected by amount of DNA/well. Samples of total
RNA were analyzed by formaldehyde/agarose gel electrophoresis to assess tissue viability at
the end of culture.
RIA
Concentrations of progesterone in conditioned media were determined as described
previously (Komar et al. 2001). The intra- and inter-assay coefficients of variation were
2.3% and 13.9% respectively.
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PCR
Total RNA was extracted from cultured tissues using Trizol reagent. Complementary
DNA was synthesized using SuperScript II Reverse Transcriptase and oligo (dT) random
primers (Invitrogen). The cDNA obtained was analyzed by PCR to determine the expression
of 20 - hydroxysteriod dehydrogenase (20-HSD) and bcl-2 in luteal tissue. S16 and
GAPDH were also analyzed and used as internal controls (Ko et al. 1999, Mendoza-
Rodriguez et al. 2003). Primers utilized for 20-HSD (Sugino et al. 1997), bcl-2, GAPDH
(Mendoza-Rodriguez et al. 2003) and S16 (Ko et al. 1999) were published previously.
PCR reactions (25µl) for 20-HSD and S16 consisted of 2.5 mM MgCl2, 1X PCR
buffer (200 mM Tris-HCl, 500 mM KCl), 2 µM of forward and reverse primers for both
genes, 200 µM dNTPs, 1.0 unit of Taq polymerase, 10x bovine serum albumin (BSA) and 50
ng of cDNA. All amplifications were carried out for 30 cycles with denaturation at 95°C for
2 minutes, annealing at 65°C for 1 minute, and extension at 72°C for 1 minute per cycle.
PCR reactions (25 µl) for bcl-2 and GAPDH consisted of 20 mM Tris-HCl (pH 8.3),
50 mM KCl, 1.0 mM MgCl2, 0.2 mM dNTPs, 0.5 µM of forward and reverse primers for
both bcl-2 and GAPDH, 2.5 units of Taq DNA polymerase and 50 ng of cDNA for GAPDH,
and 500 ng of cDNA for bcl-2. All amplifications were carried out for 35 cycles, with
denaturation at 95°C for 5 minutes, annealing at 60°C for 1 minute, and extension at 72°C for
5 minute per cycle.
Samples were analyzed in duplicate, and the analysis repeated three times. PCR
products were separated on a 2% agarose gel. Densitometric analysis of the resulting bands
was conducted using the Spot Denso program (Fluorchem, Alpha Innotech). Relative levels
of 20-HSD and bcl-2 were determined in relation to S16 and GAPDH, respectively, per
sample.
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Immunohistochemistry
Paraffin embedded ovarian tissue was serially sectioned at 5 µm. Consecutive
sections were processed for immunodetection of PPAR and macrophages. Paraffin sections
were dewaxed in xylene and rehydrated through a series of rinses in decreasing ethanol
solutions. Antigen retrieval was performed by placing slides in 0.01M Tris (pH=8.5) in a
microwave on high heat for 10 minutes. After cooling, slides were placed in 1.5% H2O2 in
methanol to quench endogenous peroxidase activity. After rinsing with PBS (pH=7.2), slides
were blocked with 10% normal horse (macrophage) or goat (PPAR) serum. Slides were
then incubated with either a monoclonal antibody against rat monocytes/macrophages (ED1
clone, Chemicon, Temecula, CA) at a 1:200 dilution for 1 hour at 37°C, or an antibody
against PPAR (E8, Santa Cruz, CA) at a 1:50 dilution overnight at 4°C. Slides were rinsed
with PBS and subsequently incubated with a species specific biotinylated secondary antibody
at a 1:200 dilution for macrophage detection (Vector Lab Inc, Burlingame CA) or 1:50
dilution for PPAR detection (Amersham). Slides were rinsed in PBS and treated with an
avidin-peroxidase complex (ABC kit; Vector Lab Inc). To visualize the immunocomplex, 3,
3’-diaminobenzidine tetrahydrochloride (DAB) was used. Slides processed for
immunodetection of macrophages were counterstained with hematoxylin. All slides were
mounted with Permount. For detection of both macrophages and PPAR, a minimum of one
control slide (blocking serum used in place of primary antibody) and two treated slides were
examined per rat (4 ovarian sections/slide).
Statistical analysis
Differences in levels of mRNA for 20-HSD and bcl-2 were analyzed by ANOVA
(SAS Version 8.2, SAS Institute, Cary, NC) followed by the Student Newman Kuels test for
comparisons of multiple groups when appropriate (JMP 5.1). Concentrations of progesterone
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in conditioned media from old and new CL were log transformed and analyzed
independently by ANOVA. A p-value  0.05 was considered significant.
RESULTS
To investigate the relationship between PPAR and progesterone production, mRNAs
for SCC and PPAR were localized in luteal tissue from naturally cycling rats by in-situ
hybridization. New and old CLs were differentiated histologically, with new CLs containing
more luteal cells and less stromal elements than old CLs (Malven & Sawyer 1966, Gaytan
1997, Simpson 2001). An inverse relationship was observed between the expression of
mRNA for SCC and PPAR. The expression of mRNA for SCC was greater in newly
forming luteal tissue compared with that observed in old luteal tissue on all days of the cycle
(Fig. 3.2). In contrast, the expression of mRNA for PPAR was greater in old luteal tissue
compared to newly forming luteal tissue (Fig. 3.3). The expression of mRNA for PPAR
appeared in a punctate pattern in some luteal tissue, most notably on the day of diestrus (Fig.
3.3 j).
Because of the inverse relationship between mRNA for SCC and PPAR in luteal
tissue with PPAR being expressed at a higher level in old CL versus new CL, we
investigated the potential of PPAR to influence the metabolism of progesterone. Levels of
mRNA for 20-HSD, the enzyme responsible for the breakdown of progesterone into its
inactive metabolite, were measured in luteal tissue collected on the day of estrus and cultured
with ciglitazone or PGJ2. Messenger RNA for 20-HSD was expressed in new and old CL,
but expression did not change in response to treatment with either PPAR agonist (Fig. 3.4).
Luteal tissue from the days of proestrus, estrus, metestrus, and diestrus was cultured
in vitro to determine how activation or inhibition of PPAR would impact progesterone
production throughout the estrous cycle. Old and new CLs were separated and cultured with
ciglitazone (65 µM) or GW-9662 (1 µM). There was no effect of activating or inhibiting
PPAR on progesterone production by new or old CLs collected throughout the estrous cycle
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(Fig. 3.5 a & b). However, administration of GW-9662 to old CL on proestrus tended to
increase progesterone production compared to controls (p = 0.06, Fig. 3.5 b). The secretion
of progesterone in vitro by fully functional luteal tissue collected from pseudopregnant rats
was also not affected by treatment with either PGJ2 or GW-9662 (data not shown).
PPAR and macrophages were immunolocalized in serial tissue sections of ovaries
collected throughout the cycle and during pseudopregnancy to determine if the expression of
PPAR in CLs corresponded to macrophages within the tissue. Positive staining for ED1
(macrophages) was observed in luteal tissue from cycling (Fig. 3.6 a-d) and pseudopregnant
(Fig. 3.6 e) rats. Luteal tissue on the day of diestrus contained low levels of labeling for ED1
(Fig. 3.6 d) relative to the other days of the cycle. Protein corresponding to PPAR was
detected in the nuclei of luteal cells on all days of the cycle, albeit at a lower level than in
granulosa cells of developing follicles (Fig. 3.7 a). Protein corresponding to PPAR was also
observed in nuclei of luteal cells during pseudopregnancy at a relatively low level (data not
shown).
The role of PPAR in luteal cell survival was investigated by measuring levels of
mRNA for bcl-2 in tissue collected throughout the cycle and cultured with ciglitazone or
GW-9662. In newly forming luteal tissue collected on all days of the cycle except diestrus,
treatment with ciglitazone reduced levels of mRNA for bcl-2 compared to controls (Fig. 3.8
a, p < 0.05, within day of the cycle). However, the administration of ciglitazone to old CL in
vitro resulted in a decrease in levels of mRNA for bcl-2 only when the tissue was collected
on the day of estrus (Fig. 3.8 b, p < 0.05, within the day of the cycle). Interestingly, treating
luteal tissue in vitro with the PPAR antagonist, GW-9662, also reduced levels of mRNA for
bcl-2 in both new and old CL collected on the days of proestrus and diestrus, as well as new
CL collected on metestrus (Fig. 3.8 a & b, p < 0.05, within day of the cycle).
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DISCUSSION
PPAR has been detected in ovarian tissue from several species. However, at this
time, it is unknown how this transcription factor impacts ovarian function. Research
conducted by Cui et al. (2002) demonstrated that in transgenic mice with the expression of
PPAR disrupted in the ovary, the females were sub- or infertile (Cui et al. 2002). Because
the expression of PPAR was not disrupted in the uterus of these transgenic animals, the
authors concluded that the lesion causing the sub- and infertility resided in the ovary. These
authors reported that on the day of estrus, circulating concentrations of progesterone were
50% lower in animals with PPAR disrupted in the ovary compared with controls, although
the difference was not significant most likely due to the small sample size (n=4). In cattle,
agonists of PPAR were found to stimulate progesterone production from mid-phase luteal
cells over a 24 hour culture period (Lohrke et al. 1998). Treatment of human granulosa-
lutein cells with PGJ2 had no effect on basal progesterone production, but inhibited LH-
stimulated progesterone production (Willis et al. 1999). Taken together, these data suggest
that PPAR may influence the ability of luteal tissue to produce progesterone, which is
necessary for the establishment and maintenance of pregnancy.
The data presented here illustrate that PPAR is not a major player in progesterone
production in the rat CL. In luteal tissue collected throughout the estrous cycle, as well as
from pseudopregnant rats, there was no significant effect of PPAR agonists or the antagonist
on progesterone production. Our data also show that there is an inverse relationship between
the expression of PPAR in luteal tissue and the ability of that tissue to produce progesterone
- as determined by levels of mRNA for SCC. These data agree with a previously published
report on the gonadotropin-treated immature rat where an inverse relationship between the
expression of mRNA for PPAR and SCC in granulosa cells was detected during the
periovulatory period (Komar & Curry 2003). These findings indicate that down-regulation
of PPAR may be important for the change in gene expression involved in luteinization and
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the switch in steroid production from estrogen to progesterone in the rat. The finding in the
current study that an antagonist of PPAR tended to increase progesterone production by
cultured luteal tissue further supports the hypothesis that down regulation of PPAR may be
important for periovulatory progesterone production in the rat. These findings differ from
those reported by Lohrke et al. (1998) and could be the result of differences in culture
methods and/or species differences in luteal development and function. The current study
utilized hemisected luteal tissue in vitro, whereas Lohrke et al. (1998) cultured dispersed
luteal cells (Lohrke et al. 1998). Separation of large and small luteal cells alters
steroidogenesis. Dispersed luteal cells produced lower amounts of hormones in vitro
compared to intact tissue from the same CL ( Pate & Nephew 1988, Jaroszewski et al. 2003).
Therefore, the use of intact luteal tissue provides a more accurate model of in vivo luteal
function. In cycling rodents, mating or cervical stimulation is necessary for the development
of fully functional corpora lutea. In contrast, after ovulation in cattle, luteal tissue develops
regardless of whether the female is mated. The hormonal environment of the luteal phase
also differs between the rat and cow. In the rat the hormone prolactin is needed for luteal
development and demise (Freeman et al. 2000), while prolactin does not play a role in luteal
function in cattle (Niswender et al. 2000).
Another difference between the bovine and rat is that the rat ovary contains CLs from
past ovulations (old CLs) as well as CLs from the most recent ovulation (new CLs). Multiple
cycles are needed for the complete regression of old CLs (Freeman et al. 2000). This is in
contrast to the bovine, whose luteal tissue develops from the most recent ovulation and
regresses in the open animal before the next estrous cycle. In the rat, the secretion of
progesterone from newly forming luteal tissue increases on the evening of proestrus. By
diestrus, there is an increase in the activity of 20-HSD, the enzyme responsible for
converting progesterone into its inactive metabolite, 20-hydroxyprogesterone (Diaz et al.
2002). A decrease in progesterone may trigger the increase in expression of 20-HSD,
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leading to progesterone catabolism (Stocco et al. 2001). In a study by Yoshida et al. (1999),
the expression of 20-HSD was greater in new luteal tissue collected at the end of
pseudopregnancy compared with that at the beginning (Yoshida et al. 1999). This expression
pattern of 20-HSD most likely reflects the fact that at the beginning of pseudopregnancy,
luteal tissue would secrete progesterone which is needed for the establishment and
maintenance of pregnancy, whereas at the end of pseudopregnancy a decline in progesterone
would correspond with parturition at the end of gestation. In the current study, agonists of
PPAR had no effect on the expression of mRNA for 20-HSD in either new or old luteal
tissue. These findings indicate that just as PPAR is not a major player in progesterone
production, it also does not affect the breakdown of progesterone via regulating the
expression of mRNA for 20-HSD.
Regression of the CL involves functional (decrease in progesterone production), and
structural changes (regression of luteal tissue, apoptosis, and macrophage infiltration) to the
tissue. Accumulation of macrophages in CL has been found to occur from the evening of
proestrus to the morning of estrus in the rat (Gaytan et al. 1998). The current study
examined the expression of macrophages in both the naturally cycling and pseudopregant rat
models. In the cycling rat, prolactin is necessary for the establishment of the macrophage
population in new luteal tissue as well as for the influx of monocytes and macrophages into
regressing CLs (Gaytan et al. 1997). Immunodetection of macrophages and PPAR in serial
sections of ovarian tissue demonstrated that they are localized primarily to different areas
within luteal tissue. Macrophages were situated mostly around luteal cells, while PPAR
was detected in the nuclei of luteal cells. Therefore, the higher expression of PPAR in old
luteal tissue compared to newly forming luteal tissue is not due solely to the presence of
macrophages within the tissue. The lack of correlation between PPAR and macrophages
may be due to the fact that the antibody used in the current study recognizes both monocytes
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and macrophages. PPAR is expressed in activated macrophages and therefore would not
colocalize with monocytes.
Apoptosis, or programmed cell death, plays a role in luteal regression. Apoptosis is
modulated by a number of regulatory genes, such as bcl-2. Bcl-2 is a member of the B-cell
leukemia/lymphoma family, and plays a role in cell survival in the ovary. In the human and
rodent, protein corresponding to bcl-2 has been detected in the corpus luteum and granulosa
cells (Richards 1994, Rodger et al. 1998, Leng et al. 2001, Kim & Tilly 2004). As
mentioned previously, the human gene encoding bcl-2 contains a peroxisome proliferator
response element (Butts et al. 2004). Because bcl-2 and PPAR are located in the same
tissues within the ovary, PPAR may affect ovarian cell survival via regulating the
expression of bcl-2. In support of that hypothesis, a study using cultured granulosa cells
showed that treatment with the PPAR agonist, troglitazone, decreased protein levels for bcl-
2 (Lovekamp-Swan & Chaffin 2005). In the current study, levels of mRNA for bcl-2 in old
CL were reduced by treatment with a PPAR agonist when the tissue was collected on the
day of estrus, and by treatment with a PPAR antagonist when tissue was collected on
proestrus and diestrus. This reduction in mRNA for bcl-2 in response to both an agonist and
antagonist of PPAR was also seen in new CL collected on proestrus and metestrus. These
apparent incongruous findings of both an agonist and antagonist of PPAR inhibiting
expression of mRNA for bcl-2 may be due to PPAR -dependent and -independent effects of
these agents. Ciglitazone is a member of the thiazolidinedione (TZD) family of drugs.
Troglitazone, another TZD, has been shown to have cellular effects that are not mediated by
activation of PPAR (Chawla et al. 2001), and reportedly can have direct effects on ovarian
cells (Gasic et al. 2001). GW-9662 has also been shown to act as a PPAR agonist in a
normal human mammary epithelial cell line (Allred & Kilgore 2005). Further study is
warranted to determine how activation/inhibition of PPAR impacts luteal cell survival.
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In conclusion, our data suggest that PPAR does not play a significant role in
progesterone production in the naturally cycling or pseudopregnant rat. The expression
pattern of PPAR is inversely related to the ability of luteal tissue to produce progesterone,
and agonists of PPAR had no effect on the ability of luteal tissue to secrete or breakdown
progesterone. PPAR is located in the nucleus of luteal cells where it may influence luteal
cell survival via regulating the expression of bcl-2. Future studies are needed to further
investigate the role of PPAR in luteal cell apoptosis and how its varying expression is
regulated during the lifespan of the CL.
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Figure 3.1. Image of an ovary collected on the day of metestrus from a naturally
cycling rat. New luteal tissue is more vascularized than old luteal tissue (a). Arrows ()
denote new luteal tissue, asterisk (*) denotes old luteal tissue. Histological image of old and
new luteal tissue (b). OCL, old luteal tissue; NCL, new luteal tissue.
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Figure 3.2. Localization of mRNA corresponding to SCC in ovarian tissue collected
from rats on the day of proestrus (a, b and c), estrus (d, e and f), metestrus (g, h and i), and
diestrus (j, k and l). Tissue sections (10 µM) were hybridized with 35S-labeled sense and
antisense riboprobes as described in the Materials and Methods. The first column represents
darkfield images of ovarian tissue sections labeled with an antisense riboprobe (a, d, g, j) with
the corresponding brightfield image in the second column (b, e, h, k). Darkfield images of
tissue hybridized with a sense riboprobe appear in the third column (c, f, i, l). GC = Granulosa
Cells, OCL = old luteal tissue, NCL = new luteal tissue. Original magnification = 100X.
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Figure 3.3. Localization of mRNA corresponding to PPAR in ovarian tissue
collected from rats on the day of proestrus (a, b and c), estrus (d, e and f), metestrus (g, h and
i), and diestrus (j, k and l). Panels a and b contain an inset image of a NCL from another area
of the ovary for comparison. Tissue sections (10 µM) were hybridized with 35S-labeled sense
and antisense riboprobes as described in the Materials and Methods. The first column
represents darkfield images of ovarian tissue sections labeled with an antisense riboprobe (a,
d, g, j) with the corresponding brightfield image in the second column (b, e, h, k). Darkfield
images of tissue hybridized with a sense riboprobe appear in the third column (c, f, i, l). GC =
Granulosa Cells, OCL = old luteal tissue, NCL = new luteal tissue. Original magnification =
100X.
53
Figure 3.4. Relative levels of mRNA (mean ± S.E.M.) for 20-HSD in rat luteal
tissue on the day of estrus as described in the Materials and Methods. The image depicts
PCR products for 20-HSD and S16 with corresponding levels of mRNA for 20-HSD in
new and old CL cultured alone (control) or with ciglitazone (65 µM) or PGJ2 (25 µM). OCL,
old luteal tissue, NCL, new luteal tissue.
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Figure 3.5. Progesterone production (mean ± S.E.M.) by new (a) and old (b) luteal
tissue collected from naturally cycling rats on all days of the cycle and cultured alone
(control) or with ciglitazone (65 µM) or GW-9662 (1 µM).
55
Figure 3.6. Immunodectection of macrophages (brown color) in sections of
ovarian tissue collected from rats on proestrus (a), estrus (b), metestrus (c), diestrus (d)
and during pseudopregnancy (e). Tissue section from an ovary collected on the day of
proestrus with normal horse serum used in place of the primary antibody as a control (f).
Original magnification = 50X.
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Figure 3.7. Immunodectection of PPAR (a and c) and macrophages (b and d)
in consecutive tissue sections of new (a and b) and old (c and d) CL in ovaries collected
from rats on proestrus. Original magnification =100X. Arrows indicate labeling for
PPAR in the nuclei of luteal cells. GC = Granulosa Cells.
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Figure 3.8. Relative levels of mRNA for bcl-2 and GAPDH in rat luteal tissue
collected throughout the cycle as described in the Materials and Methods. (a) PCR
products for bcl-2 and GAPDH with corresponding levels of mRNA for bcl-2 in new CL
cultured alone (control) or with ciglitazone (65µM) or GW-9662 (1µM). (b) PCR
products for bcl-2 and GAPDH with corresponding levels of mRNA for bcl-2 in old CL
cultured alone (control) or with ciglitazone (65µM) or GW-9662 (1µM). Bars with
different superscripts denote significant differences within the day of the cycle (p <
0.05).
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CHAPTER 4. DEVELOPMENT OF MODELS TO
FACILITATE INVESTIGATION OF OVARIAN GENES
REGULATED BY THE TRANSCRIPTION FACTOR,
PEROXISOME PROLIFERATOR-ACTIVATE RECEPTOR 
NS Tinfo, LJ Luense, P Liu, and CM Komar
ABSTRACT
Peroxisome proliferator-activated receptor  (PPAR) is a transcription factor that has
been found to be involved in many processes such as steroidogenesis, angiogenesis, and
tissue remodeling. These processes are critical for normal ovarian function. PPAR has
been detected in granulosa, theca, and luteal cells. Previous studies have identified that
PPAR is differentially expressed in granulosa cells in the ovary during the ovarian cycle.
However, the roles of PPAR in the ovary have not been determined.
Previous attempts to create a PPAR knock-out mouse resulted in an embryonic lethal
phenotype, making it difficult to investigate the role of PPAR in the ovary. Therefore, to
determine the role(s) of PPAR in ovarian biology, cre/loxP technology was used to create
two models, one in vivo and one in vitro, with reduced expression of PPAR specifically in
ovarian tissue. These two models allowed for the discovery of candidate genes regulated by
PPAR and will allow for further study of this transcription factor in ovarian biology.
INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are transcription factors and
members of the nuclear receptor superfamily [1]. There are three isotypes of PPARs: , ,
and . The PPARs have been found to be involved in many processes, such as
steroidogenesis, angiogenesis, and tissue remodeling. These processes are critical for normal
ovarian function. All three PPAR isotypes have been identified in the ovary [2], but only
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PPAR is differentially expressed. Certain ligands of PPAR , the thiazolidinedions, are
commonly administered to patients with type II diabetes and polycystic ovarian syndrome
[3]. Since the role(s) of PPAR in the ovary has not been determined, it is not known how
activation of PPAR by these drugs is affecting female fertility.
PPAR has been detected in ovarian tissue from humans [4], pigs [5], sheep [6], mice
[7], rats [8], and cattle [9]. This transcription factor is found primarily in granulosa cells of
developing follicles. PPAR has also been detected in luteal and thecal tissue, but at a lower
level than in granulosa cells [2, 6, 8, 10]. Along with the localization of PPAR in the ovary,
previous studies have also demonstrated that agonists of PPAR can affect steroidogenesis
(reviewed in [11]). The influence of PPAR on steroid production varies within and between
species, suggesting that the endocrine environment of the animal influences how PPAR
affects ovarian function.
PPAR is present in the ovary and it has also been found to be active in ovarian cells
[6, 12, 13]. Sheep and rat granulosa cells were transfected with a reporter construct driven
by PPAR responsive elements [6, 13]. With or without addition of an agonist, there was an
increase in reporter activity [6, 12, 13]. The increase in reporter activity in the absence of
exogenous ligand indicated that PPAR is active in granulosa cells and that an endogenous
ligand is present in these cells.
Several studies have indicated that PPAR plays an important role in ovarian biology.
Previous research on mice with PPAR disrupted in mammary epithelium, B- and T-cells,
and the ovary resulted in female mice being either sub- or infertile [7]. This study illustrates
the importance of PPAR in fertility. PPAR has also been shown to be involved in
processes other than steroid production that are critical for normal ovarian function. Two of
these processes are angiogenesis and inflammation. Angiogenesis, the formation of blood
vessels, is required for follicular growth and formation/function of corpora lutea (reviewed in
[14]). PPAR has been found to have varying effects on angiogenesis (reviewed in [15]).
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The effect of PPAR agonists on angiogenesis in the ovary has not been determined. The
promoter region of the rate limiting enzyme in prostaglandin production, cyclooxygenase-2
(COX-2), contains a response element for the PPARs [16]. Ovulation and luteolysis have
been likened to an inflammatory response [17]. Prostaglandins are involved in ovulation and
luteolysis, and are major regulators of inflammation [18]. Prostaglandins have also been
shown to be endogenous ligands for the PPAR [19]. The fact that prostaglandins are ligands
for PPAR , and that the promoter region of COX-2 contains a response element for the
PPARs, suggest that PPAR may regulate COX-2 expression in ovarian cells, and thereby
play a role in ovulation and/or luteolysis.
The exact role(s) of PPAR in the ovary has not been determined. Studying PPAR
in the ovary has been difficult due to the fact that knocking out PPAR in the genome results
in an embryonic lethal phenotype. There is a need for an experimental model that will allow
for the study of this transcription factor in ovarian function. Therefore, two models, one in
vivo and one in vitro, of reduced expression of PPAR in the ovary were developed. These
models utilized cre/loxP technology to reduce expression of PPAR in granulosa cells. The
in vivo model has been used to identify candidate genes regulated by PPAR . Future studies
will investigate how the regulation of these genes affects normal ovarian function.
METHODS AND MATERIALS
Development of an in vivo model to study the role of PPAR in the ovary
Cre/loxP technology allows for the production of mice with reduced expression of a
particular gene in a tissue selective manner. Genetic engineering is used to generate mice
expressing cre recombinase, a bacterial enzyme that recognizes and cuts at loxP sites. The
use of specific promoters to drive expression of cre recombinase results in this enzyme being
active in a tissue specific manner. Genetic engineering is also used to create mice with loxP
sites flanking a gene of interest. By crossing these two lines of mice, the tissue selective
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expression and activity of cre recominbase will recombine the gene containing the loxP sites,
resulting in tissue selective reduction in expression of that gene.
Generation of mice with reduced expression of PPAR in the ovary. All animal
procedures were approved by the Iowa State University Animal Care and Use Committee.
Two different lines of mice were mated to produce animals with reduced expression of
PPAR in the ovary. One mouse line, developed by Jamin et al. (2002), had cre recombinase
inserted into the gene encoding anti-Mullerian hormone receptor 2 (Amhr2) (Amhr2cre/wt;
generously provided by Dr. Richard R. Behringer). Amhr2 is expressed solely in the gonads
[20] and, in females, specifically in granulosa cells [21]. Mice with loxP sites inserted on
either side of exon 2 of PPAR , were generated by Akiyama et al. (2002) (PPARfl/fl, kindly
donated by Dr. Frank J Gonzalez). Homozygous PPARfl/fl mice were crossed with mice
heterozygous for insertion of cre recombinase into the Amhr2 gene (Amhr2cre/wt). The
resulting F1 progeny were genotyped and mice carrying the allele for cre recombinase
(PPARfl/wt, Amhr2cre/wt) were mated to founder PPARfl/fl mice to obtain animals
homozygous for the floxed PPAR allele and heterozygous for cre recombinase (PPARfl/fl,
Amhr2cre/wt). The resulting progeny (PPARfl/fl, Amhr2cre/wt) were backcrossed to the
PPARfl/fl founder line for six generations to minimize genetic variation.
DNA Extraction and Genotyping. Tail biopsies, approximately 0.5 cm long, were
collected from 9 to 11 day old mice. Tissues were dissolved in 465 µl of tail extraction
buffer (50 mM Tris pH 7.5, 100mM EDTA, 0.5% SDS, and 650 mg/µl proteinase K) by
incubating overnight at 55°C. The following day, 250 µl of dissolved tissue solution were
added to an equal amount of phenol:chloroform:isoamyl alcohol (25:24:1; Invitrogen), mixed
vigorously, and centrifuged at 15,000 rpm for 5 minutes at 4°C. The supernatant was
removed and extracted twice with phenol:chloroform. Following the final extraction, the
aqueous portion was removed and added to 1 ml of cold 100% ethyl alcohol to precipitate the
DNA. Samples were centrifuged at 15,000 rpm for 15 minutes at 4°C prior to supernatant
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aspiration and rinsing of the pelleted DNA with room temperature 70% ethyl alcohol. The
DNA was then vortexed and centrifuged at 15,000 rpm for 5 minutes at 4°C, the ethyl
alcohol was discarded, and the pellets allowed to air dry for 5 to 10 minutes. The pelleted
DNA was resuspended by adding 100 µl of Tris-Cl EDTA (TE) and incubating at 37°C
overnight. Concentrations of DNA were quantified by spectrophotometry. Samples were
diluted to a concentration of 10 ng/µl and stored at -70°C for future use.
Genotypes were determined by PCR at both the PPAR and Amhr2 loci. The
following primers were used to amplify the wild type, floxed, and null alleles for PPAR: F,
5’-ctc caa tgt tct caa act tac-3’, Rev1, 5’-gat gag tca tgt aag ttg acc-3’, Rev2, 5’-gta ttc tat ggc
ttc cag tgc-3’ [7]. PCR reactions consisted of 2.5 mM MgCl2, 1X PCR buffer, 10 µM of
each primer, 10 mM dNTPs, 10X bovine serum albumin, 1 U Taq polymerase (Bioline,
Boston), and 50 ng DNA in 25 µl reactions. For amplification, 35 cycles were used at 94°C
for 30 seconds, 60°C for 30 seconds, and 72°C for 90 seconds, with an initial denaturation at
94°C for 2 minutes and a final extension for 5 minutes at 72°C. Insertion of cre recombinase
into the gene encoding Amhr2 was determined by amplification of genomic DNA with the
primers: cre1, 5’-gcg gtc tgg cag taa aaa cta tc-3’, cre2, 5’gtg aaa cag cat tgc tgt cac tt-3’
(sequences from Jackson Laboratories, Bar Harbor, ME). Amplified PCR products were
separated by electrophoresis through a 2% agarose gel. PCR products representing wild-type
alleles of PPAR produced a 225 bp fragment, flox-flanked PPAR alleles a 275 bp
fragment, and the recombined, null PPAR allele produced a 400 bp fragment. The primers
for cre recombinase produced a 100 bp fragment, and no amplified product when only
Amhr2 wild-type alleles were present. Interleukin-2 (Il-2) was amplified as an internal
control (Il-2F, 5’-cta ggc cac aga att gaa afa tct-3’, Il-2R, 5’-gta ggt gga aat tct agc atc atc c-
3’, 324 bp, Jackson Laboratories). An internal control was used to verify success of the
assay. If no band was produced for the Amhr2 allele or internal control, this indicated failure
of the PCR reaction. However, if a fragment corresponding to the internal control was
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generated, but not one for Amhr2, the reaction was successful, but the mice did not have cre
recombinase inserted into the Amhr2 allele.
To validate that the expression of PPAR was reduced in the ovary of the PPAR
Amhr2 mice, PCR was performed to compare levels of the floxed and null alleles of PPAR.
Animals homozygous for the floxed PPAR allele and hetero- or homozygous for cre
recombinase (PPARfl/fl, Amhr2cre/-) had the ability to produce both non-functional,
recombined null PPAR , as well as functional, floxed PPAR alleles. Animals that did not
express cre recombinase, PPARfl/fl, Amhr2wt/wt only produced the functional floxed PPAR
allele.
Microarray Analysis. Microarray analysis was used to detect candidate genes
regulated by PPAR . Mice homozygous for the floxed PPAR allele and hetero- or
homogygous for cre recombinase (PPARfl/fl, Amhr2cre/-; n=3), and mice without cre
recombinase (PPARfl/fl, Amhr2wt/wt; n=3) were injected with 5 IU of PMSG on day 23 of
age to stimulate follicular development. Ovaries were collected 48 hours later and placed in
a sucrose/EDTA media (25 mM HEPES, DMEM: F12, 0.01% sodium pyruvate, 0.22%
sodium bicarbonate, 0.125% gentamicin, insulin-transferrin-sodium selenite media
supplement, 0.5 M sucrose, and 10 mM EDTA; pH= 7.2) at 37°C in 5% CO2: 95% air for 20
minutes. Ovaries were then rinsed and placed in defined media (25 mM HEPES, DMEM:
F12, 0.01% sodium pyruvate, 0.22% sodium bicarbonate, 1% bovine serum albumin, 0.125%
gentamicin, and insulin-transferrin-sodium selenite media supplement; pH= 7.2). Twenty-six
gauge needles were used to repeatedly puncture the ovaries, releasing the granulosa cells.
The media were collected and the granulosa cells collected by centrifugation at 700 g for 4
minutes. DNA and RNA were extracted from granulosa cells using Trizol reagent, following
manufacturer’s instructions. PCR was performed to detect the level of expression of the
PPAR alleles. RNA quality and subsequent microarry analysis was performed at the Iowa
State University Gene Chip Facility. Briefly, the RNA quality was assessed using an
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Agilient 2100 bioanalyzer. After RNA analysis, the RNA was used to produce cDNA. The
cDNA was amplified and biotinylated. The biotin-cDNA was used to hybridize to
Affymetrix mouse 430 2.0 arrays (1 array per mouse, n= 6 arrays). This array contains
45,000 probe sets to analyze the expression level of 40,000 genes. After hybridization, the
arrays were washed and scanned to determine the level of gene expression for the 40,000
genes.
Statistical Analysis. Data were analyzed in collaboration with Dr. Peng Liu at the
Iowa State University Statistics Department. Original microarray data contained genes that
were absent, present and marginal. Absent referred to genes that did not hybridize at all,
present referred to genes that hybridized and marginal referred to genes that had some weak
hybridization. When a gene was absent from all six arrays, the gene was removed from the
database. This narrowed down the list of genes for statistical analysis. The microarray data
were then analyzed by a 2-sample student t-test. A p-value of  0.01 was considered
significant.
Development of an in vitro model to study the role of PPAR in the ovary
Adenoviral technology was utilized to reduce the expression of PPAR in cultured
granulosa cells. An adenovirus will infect dividing cells and is a powerful tool to introduce a
gene(s) into cells. The adenoviruses used to infect the granulosa cells contain the gene for
green fluorescent protein (GFP; control adenovirus: Ad-CMV-eGFP), or cre recombinase in
addition to GFP (cre adenovirus: Ad5-CMVCre-GFP). Granulosa cells from PPAR fl/fl mice
were placed in culture with either the control adenovirus, or the cre adenovirus. GFP
allowed for visualization of cells that were successfully infected with the adenoviruses.
Optimization of transfection efficiency
Cell culture. Collection of granulosa cells from PPARfl/fl, Amhr2wt/wt mice was
performed as described above. The cell pellet was resuspended in 2 ml of media (25 mM
HEPES, DMEM: F12, 0.01% sodium pyruvate, 0.22% sodium bicarbonate, 0.125%
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gentamicin, insulin-transferrin-sodium selenite media supplement and 1% fetal bovine
serum; pH= 7.2) and the number of granulosa cells counted with a hemocytometer. Cells
were plated in media containing 1% fetal bovine serum at 37°C in 5% CO2: 95% air for 24
hours, to allow the cells to attach to the wells. All experiments performed to optimize
transfection efficiency were performed after the initial 24 hours of culture.
Experiments were performed to identify media type, adenovirus concentration,
plating density, and incubation time that would support efficient and effective infection of
granulosa cells. The effect of fetal bovine serum was tested because the manufacturer of the
adenovirus (Baylor Vector Development Laboratory, Houston TX) suggested using media
with fetal bovine serum. However, fetal bovine serum has been reported to interfere with
adenoviral transfection efficiency (personal communication, Dr. Boerboom). Therefore, the
control (Ad-CMV-eGFP) or cre (Ad5-CMVCre-GFP) adenovirus was added to the cells in
media with or without fetal bovine serum. The following concentrations of each adenovirus
were tested: 5, 15, 50, 100, 500, 1000, 2000, 2500, 3000 particles/cell. Plating density was
studied to optimize the growth of granulosa cells. Cells were plated at 100,000 or 200,000
cells/well. The concentrations of adenovirus and number of cells plated were chosen based
on personal communication with Dr. Boerboom and the manufacturer of the adenovirus.
Cells were cultured with the adenovirus for 24 or 48 hours at 37°C in 5% CO2: 95% air.
At the defined experimental end point, 24 or 48 hours of culture, granulosa cells were
analyzed under a Nikon phase contrast microscope to observe GFP expression to determine
the percentage of cells that were infected by the adenovirus. Granulosa cells were
subsequently collected and stored at -20°C until used for reverse transcription PCR (RT-
PCR) to determine levels of mRNA for PPAR .
RT-PCR. Total RNA was extracted from cultured granulosa cells using Trizol
reagent, following the manufacturer’s instructions. Complementary DNA was
synthesized using SuperScript II Reverse Transcriptase and oligo (dT) primers
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(Invitrogen). The cDNA obtained was analyzed by PCR to determine the relative levels
of PPAR and S16 (internal control) in cultured granulosa cells. Primers used to amplify
S16 were published previously [22]. PPAR primers were as follows: PPAR forward, 5’-
gat gaa taa aga tgg agt cct cat ctc- 3’, PPAR reverse, 5’- ccg cag gct ttt gag gaa-3’. The
PCR products generated from the PPAR primers were sequenced at the Iowa State DNA
facility to verify amplification of the desired gene.
RT-PCR reactions (25µl) for PPAR and S16 consisted of 1.25 mM MgCl2, 1X PCR
buffer (200 mM Tris-HCl, 500 mM KCl), 1 µM of forward and reverse primers for both
genes, 200 µM dNTPs, 2.0 unit of Taq polymerase, 10x bovine serum albumin (BSA), and
100 ng of cDNA for PPAR and 10 ng of cDNA for S16. All amplifications were carried out
for 35 cycles with denaturation at 95°C for 1 minute, annealing at 52°C for 1 minute, and
extension at 72°C for 1 minute per cycle. The concentrations of cDNA used for RT-PCR
reactions were within the linear range of the assay. The linear range was determined by
assessing the amount of product produced under the conditions described above when
increasing concentrations of cDNA were used in the reaction. Plotting the output versus
input indicated the concentration range of input cDNA that yielded a corresponding increase
in output.
RESULTS
To explore the function of PPAR in the ovary, an in vivo model was developed with
the expression of PPAR specifically reduced in granulosa cells. Mice with loxP sequences
flanking exon 2 of PPAR (PPARfl/fl, referred to as the flox line) were mated to mice
containing cre recombinase (referred to as the cre line). This mating resulted in the crox line
of mice. Due to the recombination activity of cre recombinase in the ovaries of crox mice
(PPARfl/fl, Amhr2cre/-) a shortened, non-functional, or null product, of the PPAR gene may
be produced, as well as and a functional (flox) band. The degree to which the expression of
PPAR was reduced in the ovary of crox females was determined by comparing the amount
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of ovarian genomic DNA encoding the floxed allele for PPAR to that encoding the PPAR
null-allele (Figure 4.1). The flox animals do not express cre recombinase (PPAR fl/fl,
Amhr2wt/wt) and therefore, produce only a functional, floxed PPAR allele (Figure 4.1). All
crox mice had approximately a 50% reduction in the expression of PPAR .
In order to investigate what ovarian genes are regulated by PPAR , a microarray
experiment was performed to determine those genes differentially expressed in granulosa
cells with PPAR unaltered compared to granulosa cells with reduced expression of PPAR .
Granulosa cells were collected from six animals (Figure 4.2; n=3: PPAR fl/fl, Amhr2cre/wt,
n=3: PPAR fl/fl, Amhr2wt/wt) and RNA was extracted and analyzed by microarray. Initial
analysis of the microarray data found the genes in Table 1 to be significantly up-regulated by
PPAR , and the genes in Table 2 to be significantly down-regulated by PPAR .
An in vitro model of reduced expression of PPAR in the ovary will also allow for
investigating the roles of PPAR in ovarian biology. Granulosa cells from flox mice were
cultured with an adenovirus containing cre recombinase to reduce the expression of PPAR
in vitro. Experiments were conducted to establish conditions for optimal transfection of the
granulosa cells, assessed by reduced expression of mRNA for PPAR.
The absence of fetal bovine serum in the culture media reduced the level of mRNA
for PPAR as determined by PCR. When four different concentrations of adenovirus were
added to the granulosa cells in culture with and without fetal bovine serum, only one
concentration of adenovirus decreased levels of mRNA for PPAR . However, when fetal
bovine serum was removed from the media three of the four concentrations of adenovirus
were able to decrease levels of mRNA for PPAR . Therefore, media without fetal bovine
serum were used for the remaining experiments.
Experiments were conducted to determine the amount of adenovirus that would result
in the most efficient transfection of granulosa cells. The most consistent reduction of mRNA
for PPAR was found when cells were cultured with either 1000 or 2500 viral particles per
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cell (pts/cell). Treatment with 1000 and 2500 virual particles per cell resulted in
approximately a 25% to 50% reduction in levels of mRNA for PPAR as compared to the
corresponding control. While treatment with the other concentrations (5, 15, 50, 100, 500,
3000 particles/cell) of adenovirus resulted in either no change in the levels of mRNA for
PPAR , an increase in levels of mRNA for PPAR or approximately a 10% decrease in levels
of mRNA for PPAR . Therefore, the remaining experiments were performed using these two
concentrations of adenovirus.
Plating density was investigated to optimize growth of granulosa cells. The granulosa
cells were plated at two different concentrations: 100,000 and 200,000 granulosa cells per
well. These concentrations of cells per well were chosen based on suggestions from the
manufacturers of the adenovirus and from personal communication with Dr. Boerboom who
had previously used this adenovirus with granulosa cells in culture. Using 1.0 x 105 cells per
well, neither adenovirus concentration was able to decrease expression of PPAR (Figure 4.3
a). As seen in Figure 4.3, a cell density of 200,000 cells/well resulted in both concentrations
of adenovirus decreasing the expression of mRNA for PPAR (Figure 4.3 b). Overall, the
best transfection efficiency and most consistent reduction of mRNA for PPAR were
observed using 2.0 x 105 cells per well and 1000 adenoviral particles per cell.
Finally, the length of time the cells were incubated with the adenovirus was
investigated. The greatest reduction of mRNA for PPAR was found after the initial 24
hours of culture with the adenovirus (Figure 4.4). Incubation with the adenovirus for 48
hours resulted in either no change (1000 pts/cell) or an increase in mRNA for PPAR (2500
pts/cell; Figure 4.4).
DISCUSSION
PPAR is present in ovarian tissue. Using cre/loxP technology, Cui et al. (2002)
produced a mouse line with PPAR disrupted in mammary epithelium, B- and T-cells, and in
the ovary. This study reported that females with reduced expression of PPAR were either
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sub- or infertile [7]. Because the expression of PPAR was not disrupted in the uterus of
these transgenic animals, the authors concluded that the lesion causing the sub- and infertility
resided in the ovary. Because progesterone and estrogen production from the ovary are
needed for implantation, it is possible that the sub- and infertility in these mice resulted from
ovarian dysfunction.
Study of gene function has been greatly advanced by the development of knock-out
animals lacking a specific gene of interest. An animal model in which the expression of
PPAR is knocked-out would facilitate investigating the role of this transcription factor in
ovarian biology. Unfortunately, deletion of PPAR results in embryonic death [23].
Investigating the cause of the lethality determined that PPAR is required for placental
development. Therefore, the current experiments were undertaken to develop models of
reduced expression of PPAR in the ovary to investigate its role(s) in the ovary.
Cre/loxP technology was utilized to create models in which PPAR was selectively
reduced in the ovary. This was possible due to the creation of an Amhr2-cre mouse [24].
Amhr2 is only expressed in granulosa cells. PPAR is also primarily localized to granulosa
cells. Insertion of cre recombinase into the Amhr2 gene (Amhr2-cre mouse) allows for cre
recombinase to only be expressed in granulosa cells. Mice with loxP insertions flanking
PPAR were previously generated and the mating of these two mouse lines enable granulosa-
cell-specific reduction of PPAR.
One strategy to determine the function of PPAR in ovarian biology is to identify
potential genes that are regulated by PPAR. The creation of the in vivo model described
above allowed for the detection of these candidate genes. Initial analysis of the microarry
data obtained from the in vivo model indicated genes possibly regulated by PPAR in
granulosa cells. Further statistical analysis will be performed to investigate false discovery
rates (FDR), since it is possible that some of the significant genes were false positive and that
some of the non-significant genes were false negatives. The FDR will be set at 10% to
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determine which genes were not false positives or negatives. With the knowledge of these
genes, future studies can verify if these genes are truly regulated by PPAR in the ovary and
how this regulation influences ovarian function.
The in vivo and in vitro models created may allow investigators to resolve conflicting
data on the roles of PPAR in processes such as steroidogenesis, angiogenesis, and
inflammation. For example, Komar and Curry (2003) found there to be no correlation
between mRNA expression for PPAR and aromatase, the enzyme responsible for the
conversion of androgens into estradiol, either before or after the LH surge in Spraque-
Dawley rats [25]. Using a different strain of rat, Lovekamp-Swan et al. (2003) found that
PPAR decreased estradiol production by suppressing aromatase activity [13]. The same
conclusion was reached using human granulosa-lutein cells [10]. These studies indicate that
PPAR is involved in steroidogenesis. However, its exact role has not been determined.
Using the in vitro model described herein, it is now possible to manipulate granulosa cells
with and without PPAR present and measure hormonal responses.
The role of PPAR in fertility can also be explored with the new in vivo model. Since
PPAR is selectively reduced in the ovary, experiments can be performed to look at time to
pregnancy, pregnancy length, litter size and more. This in vivo model should allow future
researchers to focus on how PPAR is involved in fertility.
Many studies have localized PPAR in ovarian tissue but the genes that are regulated
by PPAR are still unknown. Using the models described above, researchers can begin to
explore which genes are regulated in the ovary by PPAR and which processes in ovarian
function require PPAR . Using the in vivo model described in this manuscript the candidate
genes that PPAR may regulate have been identified. Future research can focus on validating
if these genes are regulated by PPAR in the ovary and how this regulation impacts ovarian
biology.
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Figure 4.1. Amplification of PPAR from genomic DNA extracted from ovarian
tissue. Tissues were collected and analyzed by PCR as described in the Methods and
Materials. Amplification of the floxed PPAR allele (fl) produced a 275 bp DNA
fragment (flox). Due to the recombination activity of cre recombinase (cre), a non-
functional (null) product of PPAR (400 bp) was produced, as well as a 275 bp functional
(flox) band.
PPAR fl/fl,
Amhr2 wt/wt
PPAR fl/fl,
Amhr2 cre/wt
400 bp
275 bp
PCR Product Length
Animal Genotype
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Figure 4.2. Amplification of PPAR from genomic DNA extracted from
ovarian tissue from PPAR fl/fl, Amhr2 wt/wt (n=3) and PPAR fl/fl, Amhr2 cre/wt (n=3)
mice. Tissues were collected and analyzed by PCR as described in the Methods and
Materials. Amplification of the floxed PPAR allele produced a 275 bp fragment
(flox). Due to the recombination activity of cre recombinase (cre) in the ovaries of
the mice, a non-functional (null) product of PPAR (400 bp) was produced, as well as
a 275 bp functional (flox) band.
PPAR fl/fl, Amhr2 cre/wt PPAR fl/fl, Amhr2 wt/wt
400 bp
275 bp
Animal Genotype
PCR Product Length
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Figure 4.3. Effect of cell density and adenovirus concentration (particles per cell) on
the levels of mRNA for PPAR. Relative levels of mRNA for PPAR with 100,000 (a), or
200,000 (b) granulosa cells per well in the presence of 1000 or 2500 particles/cell of
adenovirus cultured for 24 hours as described in the Methods and Materials. c= control
adenovirus, cre = cre adenovirus.
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Figure 4.4. The effect of length of culture, 24 or 48 hours, on levels of mRNA for
PPAR. Relative levels of mRNA for PPAR with 200,000 granulosa cells/well cultured
with 1000 or 2500 particles/cell of adenovirus, over 24 or 48 hours, as described in the
Methods and Materials. c= control adenovirus, cre= cre adenovirus.
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TABLE 1.
Ovarian genes up-regulated by PPAR
N-Acetyltransferase 2 Interleukin Enhancer Binding Factor
Guanylate Cyclase Activator 1A Tripartite Motif Protein 8
Synaptotagmin-like Protein 3-b Neuropilin-2 
Growth Hormone Inducible
Transmembrane Protein
Serine Threonine Kinase Receptor
Associated Protein
Cartilage Derived Retinoic Acid Sensitive
Protein
SH2-B PH Domain Containing Signal
Mediator 1
Ras-GTPase-Activating Protein Cyclic Nucleotide-Gated Channel Beta
Truncated Class I MHC Receptor Furmin BP-1 
Calmodulin 2 F-box and WD-40 Domain Protein 13
Class 1 Major Histocompatibility Antigen Seryl-Aminoacyl-tRNA Synthetase 2
Bladder Cancer Associated Protein Putative Mannosyltransferase
Nuclear Factor of Activated T-Cells Acetyl CoA Transferase-like Protein
Guanosine Diphosphate Dissociation
Inhibitor 3
Huntingtin Associated Protein
Paraoxonase 2 Amyloid Beta Precursor-like Protein
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TABLE 2.
Ovarian genes down-regulated by PPAR
F-box only Protein 32 Mercaptopyruvate Sulfurtransferase
Diazepam Binding Inhibitor Procollagen Type V, alpha-3 
Protein Tyrosine Phosphatase, Receptor
Type K
Tumor Associated Calcium Signal
Transdurcer 1
ATPase, Na+ K+ Transporting Beta 1
Polypeptide
Calcium Calmodulin-Dependent Protein
Kinase 1
Calcineurin Inhibitory Protein ZAK1-4 Granzyme A
J Domain Protein 1 Guanylate Nucleotide Binding Protein 3
Procollagen, Type IX, Alpha 3 Phosphatidylinositol 3-Kinase
T-Cell Lymphomia Invasion and
Metastasis 1
Protein Tyrosine Phosphatase Receptor
Type E
Metal Response Element Binding
Transcription Factor 1
Apoptosis Inhibitor 1
Adenosine Kinase Serum Inducible Kinase
Protein Inhibitor of Activated STAT 1 ATP-Binding Cassette, sub-family C
T-cell Receptor Beta-Chain Protocadherin 8
Kruppel-like Factor 9
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CHAPTER 5. EFFECT OF GENISTEIN ON ESTRADIOL
PRODUCTION BY BOVINE FOLLICLES
Submitted for Publication in Reproductive Toxicology
NS Tinfo, LJ Luense, SM Hopkins, and CM Komar
ABSTRACT
Genistein, a phytoestrogen present in food commonly found in human and animal
diets, can affect various aspects of ovarian biology. We investigated the effect of genistein on
follicular estradiol production. Ovaries were removed from heifers (n=3) when the largest
follicle measured approximately 8 mm. The largest and second largest follicles were
dissected from the ovary, and pieces of follicle wall placed in culture with vehicle, FSH (1
ng/ml), genistein (10 µM), FSH + genistein, or vehicle or genistein (10 µM), respectively.
There was no effect of treatment on estradiol production by cultured follicular tissue from the
largest or second largest follicle. However, there was a decrease in levels of mRNA for
aromatase in tissue from the largest follicle treated with genistein + FSH, compared to that
treated with FSH alone (p0.05). These data suggest that genistein may not affect the basal
production of estradiol, but may alter response to gonadotropin stimulation.
INTRODUCTION
Phytoestrogens are biologically active plant substances with a chemical structure
similar to that of estradiol [1]. There are three main classes of phytoestrogens: isoflavones,
coumestans, and lignans [2]. Isoflavones and coumestans are contained in legumes, which
are common components of human and animal diets.
Soybean is an abundant source of isoflavones [3], and one of the most abundant
isoflavones in soybean is genistein [4]. Animals, such as cattle and sheep, are exposed to soy
phytoestrogens via grazing and silage [5]. At least 25% of the infant formula marketed in the
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United States is comprised of soy based products [6]. Manufacturers are adding soy protein
to food as a result of the FDA-supported claim concerning their cardiovascular protection.
Recent health trends have also spurred the consumption of soy protein in adult diets with
increased intake of foods such as tofu and soy milk. The use of genistein as a nutraceutical
has also exploded in recent years. Supplements containing genistein are being studied for
treating ailments such as cancer [7], menopausal symptoms, and osteoporosis (reported in
[8]).
Within the plant, genistein is an inactive glucoside. Once genistein is ingested it is
converted into a heterocyclic phenol [2]. This heterocyclic phenol is structurally similar to
estrogen and capable of inducing estrogenic and/or anti-estrogenic effects [2, 9]. In cattle,
the specific heterocyclic phenol generated from genistein, p-ethyl-phenol, has been detected
in the blood for many hours after consumption of feed containing soybean [10].
Genistein may affect ovarian biology by modulating the activity of second messenger
systems. Specifically, genistein inhibits tyrosine kinases, important intracellular second
messengers involved in steroidogenesis. Inhibition of tyrosine kinases could lead to a
decrease in ovarian hormone production [11].
Along with the ability of genistein to impact hormone production, it may also affect
the activity of estradiol. Production of estrogen by granulosa cells is required for the LH
surge and ovulation. Estrogen receptor  (ER) has been identified in several ovarian cell
types, primarily granulosa cells [12-14]. Genistein binds with a greater affinity to ER than
ER [15]. Genistein competes with endogenous estrogen for binding to ER. Genistein has
both estrogenic and anti-estrogenic activity [2, 4]. The effect of genistein being either
estrogenic or anti-estrogenic, depends on the tissue type, ER, and concentration of circulating
endogenous estrogens [16, 17].
Genistein could potentially regulate ovarian gene expression not only by interacting
with ERs, but also through binding to peroxisome proliferator-activated receptor  (PPAR)
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[18]. Like ERs, PPAR is a member of the steroid receptor superfamily, and is expressed in
ovarian tissue of several species, including the mouse, rat, cow, sheep, pig, and human [19].
Genistein binds and activates PPAR [18, 20]. Dang et al. (2003) found that when genistein
activates PPAR , there is a decrease in the activity of estrogen. This effect of genistein is
dependent on the concentration of genistein, and the levels of ER and PPAR within the
tissue [20]. The decrease in estrogenic activity could be due to the fact that PPARs compete
with endogenous estrogens for binding to estrogen response elements [21, 22]. Activation of
PPAR can also influence various processes such as angiogenesis, inflammation, and
steroidogenesis (reviewed in [14]). These processes are critical for normal ovarian function.
Therefore, activation of PPAR by genistein may also affect reproduction by regulating
several processes involved in normal ovarian function.
Since humans and animals are exposed to genistein via the diet, and because this
phytoestrogen may affect ovarian function, the following experiments were performed to
investigate how genistein may influence follicular estradiol production. We hypothesized
that exposure to genistein would decrease follicular production of estradiol.
METHODS AND MATERIALS
Animals
All animal procedures were approved by the Iowa State University’s Animal Care
and Use Committee. Fifteen to eighteen month old, cyclic Angus heifers (n=3) were
monitored by transrectal ultrasonography to follow follicular development, ovulation, and
growth and regression of the corpus luteum (CL). Two perpendicular diameters of ovarian
structures larger than 5 mm were recorded. Diagrams were made of the relative positions of
follicles and CL to monitor follicular growth and luteal formation/regression. Day 1 of the
cycle was defined as the first day the ovulatory-sized follicle was no longer observed. To
synchronize the day of ovulation, two heifers received 25 mg of Lutalyse (Pharmacia,
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Peapack, NJ) to regress the CL, followed thirty-six hours later by an injection of a GnRH
analog (Cystorelin; 100 µg) to induce an LH surge. The remaining heifer cycled naturally.
Before removal of the ovaries by flank incision, the heifers received an “L” block
with 2% lidocaine. Ovaries were removed from all heifers when a follicle from the first
follicular wave post-ovulation measured approximately 8 mm. This size was chosen because
it is at this relative developmental stage when deviation occurs between dominant and
subordinate follicles [23]. After removal, ovaries were immediately placed in ice-cold
transfer medium [minimum essential medium (Gibco, Carlsbad, CA), 2.2% NaHCO3,
penicillin (50 U/ml), streptomycin (50 µg/ml)] and transported to the laboratory. The two
largest follicles were dissected from ovaries within 30 minutes of removal from the heifer.
Follicular fluid was collected and frozen at -20°C until analyzed for estradiol by RIA.
Follicular tissue was cultured in vitro as described below.
Tissue Culture
The largest and second largest follicles were hemisected and cut into pieces. Tissues
(n=three pieces per well) were cultured in 500 µl of media [minimum essential medium,
2.2% NaHCO3, 25 mM HEPES, penicillin (50 U/ml), streptomycin (50 µg/ml), transferrin (5
µg/ml), cortisol (40 ng/ml), and insulin (1 µg/ml)], with the following treatments: largest
follicle – vehicle (methanol; control), FSH (1 ng/ml), genistein (10 µM), or FSH + genistein;
second largest follicle – vehicle or genistein (10 µM). The concentration of FSH used in this
study has been found to support steroid production typical of the follicular phase in vivo [24].
The dose of genistein was chosen because it had been previously found to elicit a
physiological effect in ovarian cells [25]. Tissues were incubated at 37°C in a 5% CO2/95%
air environment for 24 hours. After culture, media were collected and stored at -20°C until
analyzed for estradiol by RIA. Tissues were weighed and frozen at -70°C until future
analysis.
85
Radioimmunoassay
Concentrations of estradiol in follicular fluid and media were determined by RIA
(DPC, Los Angeles, CA), according to the manufacturer’s directions. The concentrations of
estradiol in media were corrected by the weight of the cultured follicular tissue in each well.
The inter- and intra-assay coefficients of variation were 4.49% and 1.57%, respectively.
Reverse Transcription-PCR
Total RNA was extracted from cultured tissues using Trizol reagent (Invitrogen), and
quantified with a spectrophotometer. Complementary DNA was synthesized in a 20 µl
reaction using SuperScript II Reverse Transcriptase and Oligo (dT) primers (Invitrogen).
The cDNA obtained was analyzed by RT-PCR to determine levels of mRNA for aromatase
in follicular tissue. The ribosomal protein, 18S, and GAPDH were used as internal controls.
Primers utilized for aromatase [26], 18S [27], and GAPDH [28] were published previously.
RT-PCR reactions (25 µl) for aromatase, 18S, and GAPDH, consisted of 1.0 mM
MgCl2, 1X PCR buffer (190 mM NH4SO4, 670 mM Tris, pH 8.8; 0.1% Tween 20), 200 µM
dNTPs, and 2.5 unit of Taq polymerase. Concentrations of forward and reverse primers, and
cDNA used for PCR reactions were as follows; aromatase: 1 µM of primers and 50 or 500 ng
cDNA, 18S: 0.025 µM primers and 75 ng cDNA, and GAPDH: 0.065 µM primers and 10 ng
cDNA. All amplifications were carried out for 35 cycles with denaturation at 95°C for 1
minute, annealing at 60°C for 1 minute, and extension at 72°C for 1 minute per cycle, and
another elongation at 72° C for 5 minutes. Samples were analyzed in duplicate and the
analysis repeated three times. RT-PCR products were separated on a 2% agarose gel.
Densitometric analysis of the resulting bands was conducted using the Spot Denso program
(Fluorchem, Alpha Innotech). Relative levels of aromatase were determined per sample as a
ratio with 18S or GAPDH.
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Statistical analysis
Data were tested for normalcy and, if needed, log transformed before analysis.
Concentrations of estradiol were analyzed with one- way ANOVA with the SAS 9.1
statistical package (SAS Institute, Cary, NC). A Student’s T-test was used to analyze the
effect of treatment on levels of mRNA for aromatase. A p-value of • 0.05 was considered
significant.
RESULTS
The first wave of follicular development post-ovulation was recorded for each heifer
via transrectal ultrasonography. On the day of surgery, the follicles were measured after
removal from the ovary. The ovaries were collected from the first wave of the cycle post-
ovulation, the largest and second largest follicles were removed, and follicular fluid was
collected. The concentration of estradiol in follicular fluid collected from the largest follicle
from two of the three heifers was at least 8 times greater than that measured in follicular fluid
from the second largest follicle (data not shown). However, estradiol concentrations in
follicular fluid from the second largest follicle from the third heifer was undetectable (assay
sensitivity = 0.8 pg/ml).
Production of estradiol by tissue collected from the largest follicle from each heifer is
shown in Figure 5.1. There was a great deal of variability in response to in vitro treatments
between tissue collected from different animals. This variability could not be accounted for
by pre-surgical hormonal regimen to synchronize ovulation. Estradiol secretion by tissue
from the largest follicle collected from two heifers, #261 and #206, decreased in response to
treatment with genistein or FSH (Fig. 5.1 a & b). In contrast, the administration of FSH or
genistein to tissue collected from the largest follicle from the remaining heifer resulted in a
doubling, or greater than four-fold increase in estradiol secretion, respectively (#305; Fig. 5.1
c). Overall, there was no significant effect of any treatment on estradiol production by tissue
from the largest follicle (p > 0.05; Fig. 5.2).
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Variability in response to treatment with genistein was also observed in cultured
tissue from the second largest follicle collected from different animals. There was an
increase in estradiol production by follicular tissue from 2 of the 3 heifers (data not shown).
However, tissue from the third heifer produced less estradiol in response to treatment with
genistein (data not shown). When the estradiol values from all three heifers were combined,
treatment with genistein did not significantly affect estradiol production (p  0.05; Fig. 5.3).
After culture, RNA was isolated from follicular tissue, and levels of mRNA for
aromatase measured by RT-PCR. Levels of mRNA for aromatase were significantly lower in
tissue from the largest follicle after treatment with genistein and FSH, compared to levels in
tissue treated with FSH alone (p  0.05; Fig. 5.4). Treatment with genistein alone had no
effect on levels of mRNA for aromatase.
DISCUSSION
In the 1940s, there was an increase in the number of cases of both permanent and
temporary infertility occurring in sheep grazing on Trifolium subterraneum, a cultivar of
subterranean clover [5]. These cases of infertility stimulated interest in the estrogenic effects
of plant phytoestrogens on the female reproductive system. There is increasing evidence that
phytoestrogens can affect fertility in both animals and humans (reviewed in [2]).  Therefore,
this study was undertaken to investigate the effect of the phytoestrogen genistein, on the
ability of ovarian follicles to produce estradiol, using the cow as a model.
The current study demonstrated that genistein, at 10 µM, did not affect the production
of estradiol by the largest or second largest follicle from the first wave of follicles developing
post-ovulation. However, levels of mRNA for aromatase decreased when tissue from the
largest follicle was cultured with genistein and FSH compared to treatment with FSH alone.
Haynes-Johnson et al. (1999) previously reported that genistein inhibited FSH-stimulated
estradiol production by rat granulosa cells [29]. Taken together, these findings suggest that
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genistein interferes with gonadotropin-stimulated estradiol production, but not basal
production.
Genistein is a weak inhibitor of aromatase. In ovarian tissue from trout, genistein was
found to inhibit aromatase activity, but was not as potent an inhibitor as other phytoestrogens
[30]. One reason genistein is a weak inhibitor of aromatase may be related to its structure
[31, 32]. Genistein has a 4’-hydroxyphenyl group at carbon 3, which greatly reduces the
ability of genistein to bind to aromatase. Le Bail et al. (2000) found that the structure of
genistein lends itself to be a better 3 –hydroxysteroid dehydrogenase and/or 17–
hydroxysteroid dehydrogenase inhibitor [32]. Therefore, the lack of an effect of treatment
with genistein alone on aromatase expression, as seen in the current study, could be due to
the structure of genistein.
The dose and/or length of exposure to genistein may also influence the ability of this
phytoestrogen to impact cellular function. Experiments have shown that in human
granulosa-luteal cells exposed to genistein for 48 hours, there was a decrease in mRNA for
aromatase, aromatase activity [25], and estradiol production [25, 33]. In the study performed
by Rice et al. (2006), both 10 µM and 50 µM of genistein were able to decrease aromatase
activity and estradiol production from human granulosa-luteal cells. However, only a 50 µM
dose was able to decrease estradiol production in human granulosa-luteal cells in the study by
Whitehead et al. (2002). Furthermore, a 4 hour incubation of human granulosa-luteal cells
with 50 µM genistein, resulted in a decrease in estradiol production in the presence of estrone
[33]. When human granulosa-luteal cells were cultured for 24 hours, genistein (50 µM)
significantly decreased estradiol production, but only in the presence of androstenedione and
estrone [33]. The dose of genistein used in the current experiment (10 µM) had been shown
previously to decrease activity and mRNA for aromatase over 48 hours of culture [25]. The
lack of an effect of genistein on secretion of estradiol observed in the current experiment may
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be due to the fact that follicular tissue was studied, not luteinizing cells, and that the tissues
were cultured for a shorter period of time.
The current data demonstrate that treatment with genistein, in combination with FSH,
decreased mRNA for aromatase in follicular tissue from the largest follicle when compared
to levels in tissue treated with FSH alone. However, genistein did not inhibit estradiol
production by this tissue. This apparent dichotomy between levels of mRNA and estradiol
production may be due to a time delay between the reduction in mRNA for aromatase and the
loss of aromatase activity, or greater stability of aromatase protein compared to mRNA. Due
to the observed decrease in levels of mRNA of aromatase, it is possible that exposure to a
low dose of genistein over a short period may alter an important step in ovarian hormone
production. Genistein may not affect the basal production of estradiol, but may alter the
response to gonadotropin stimulation. Further studies are needed to determine how genistein
affects follicular, as well as oocyte development, and the time course of response after
exposure and the time needed for recovery after withdrawal.
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Figure 5.1. Secretion of estradiol (pg/ml) by tissue collected from the largest follicle
of the first wave of the cycle (n=3) from individual animals. Follicular tissue was cultured as
described in the Methods and Materials with methanol (control), FSH (1 ng/ml), genistein
(10 µM) or FSH and genistein. C = control, Gen= genistein.
b# 261
26.5
10.2 9.3 8.2
0
15
30
C FSH Gen FSH + Gen
Treatment
E s
t r
a d
i o
l ( x
1 0
3
p g
/ m
l )
# 206
274.5
47.8
84.0
48.5
0
150
300
C FSH Gen FSH +
Gen
Treatment
Es
tr
ad
io
l(x
10
5
pg
/m
l)
# 305
6.5 13.6
237.8
48.2
0
125
250
C FSH Gen FSH +
Gen
Treatment
Es
tr
ad
io
l(x
10
2
pg
/m
l)
c
a
95
Figure 5.2. Secretion of estradiol (pg/ml) by tissue collected from the largest follicle
(n=3) of the first wave of the cycle. Data are presented as mean ± SEM. Follicular tissue
was cultured as described in the Methods and Materials with the following treatments:
methanol (control), FSH (1 ng/ml), genistein (10 µM) or FSH and genistein. C= control, Gen
= genistein.
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Figure 5.3. Secretion of estradiol (pg/ml) by tissue collected from the second largest
follicle (n=3) from the first wave of the cycle. Data are presented as mean ± SEM.
Follicular tissue was cultured as described in the Methods and Materials with the following
treatments: methanol (control) or genistein (10 µM). C= control, Gen= genistein.
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Figure 5.4. Relative levels of mRNA for aromatase in tissue from the largest follicle
of the first follicular wave after 24 hours of culture. Data are presented as mean ± SEM.
Follicular tissue was cultured as described in the Methods and Materials with the following
treatments: methanol (control), FSH (1 ng/ml), genistein (10 µM) or FSH and genistein. C=
control (methanol), Gen= genistein. Bars with different superscripts are significantly
different (p  0.05).
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CHAPTER 6. GENERAL CONCLUSIONS
DISCUSSION AND CONCLUSIONS
In order to improve fertility and reproductive success, it is important to understand
how genes are regulated in the ovary. One of the most frequent causes of infertility in
women is polycystic ovarian syndrome (PCOS). PCOS is characterized by formation of
cysts in the ovaries, chronic absence of ovulation, and clinic signs of hyperandrogenism.
Treatment with insulin sensitizers increases fertility in these patients. One class of drugs, the
thiazolidinediones (TZDs), are insulin-sensitizing drugs that are commonly administered to
patients with type II diabetes and PCOS (reviewed by [1]). TZDs are also ligands for
PPAR. PPAR was first located in the rat ovary in 1996, and has since been found in the
ovary of several species. To date, the role(s) of PPAR in the ovary has not been determined.
Understanding the role(s) of PPAR in the ovary will allow researchers to determine how
activating PPAR via these drugs, or other ligands, affects ovarian function and female
fertility.
PPAR is involved in processes in the body such as steroidogenesis, angiogenesis,
and inflammation, which are important for normal ovarian function. The roles of PPAR in
these processes indicate possible ways that PPAR may influence ovarian biology. The
projects described in this dissertation were conducted to investigate the role(s) of PPAR in
the ovary. The first study investigated how PPAR influences progesterone
production/breakdown and if PPAR is involved in luteal demise in the rat. Experiments
were also performed that investigated the effects of a PPAR agonist, genistein, on estradiol
production in the bovine. Models of reduced expression of PPAR in granulosa cells were
also developed as a means of investigating genes regulated by PPAR in the ovary.
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Collectively, these studies gave insight into the role(s) PPAR does and does not play in the
ovary.
PPAR has been localized in luteal tissue from several species. In the rat, luteal tissue
from past ovulations contained greater expression of mRNA for PPAR than luteal tissue
from the most recent ovulation [2]. This is in contrast to the bovine corpus luteum, where
PPAR decreases between the early and mid-luteal phase [3]. Lohrke et al. (2002)
investigated the role of PPAR in the bovine corpus luteum, and concluded that PPAR is
involved in progesterone production. However, the function(s) of PPAR in the rodent
corpora lutea was not known. This dissertation describes the experiments that were the first
to report that PPAR does not play a role in the production or catabolism of progesterone in
rat corpora lutea. Further investigations into the role(s) of PPAR in rat luteal tissue also
found that PPAR is not involved in luteal demise via macrophages. Interestingly,
experiments did demonstrate that PPAR may play a role in cell survival via regulation of the
bcl-2 gene. Since a peroxisome proliferator response element has previously been located in
the human bcl-2 gene [4], it is possible that PPAR regulates the expression of bcl-2. Future
studies are needed to determine how PPAR influences the expression of bcl-2 in the rodent
corpora lutea.
Activation of PPAR has been found to have varying effects on estradiol production.
In human granulosa-luteal cells and gonadotropin-primed rat granulosa cells, PPAR was
able to decrease the expression of mRNA for aromatase [5, 6]. However, other research has
shown that there is no correlation between the expression of mRNAs for PPAR and
aromatase in granulosa cells during folliculogenesis, or the periovulatory period [7]. The
study described in this dissertation investigated if one agonist of PPAR , genistein,
influenced estradiol production and/or aromatase expression from bovine follicles. These
preliminary studies demonstrated that follicles exposed to FSH and genistein had
significantly lower levels of mRNA for aromatase than those treated with FSH alone.
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Therefore, it was concluded that genistein does not affect the basal production of estradiol
but may alter the response to gonadotropin-stimulation. Future studies are needed to look at
longer incubation times with genistein and more doses of genistein to determine the dose
range and length of time it takes to minimally and maximally affect aromatase expression
and production of estradiol. Since activation of PPAR has been found to have varying
effects on steroidogenesis between species, investigating the effect of genistein on the ability
of bovine follicles to produce estradiol may not answer the question of how exposure to this
phytoestrogen will affect other animals exposed to genistein. Therefore, since phytoestogen
exposure also affects sheep, and PPAR is found in ovarian tissue from sheep, experiments
could also be performed that investigate the effects of PPAR on steroid production from
sheep ovarian cells.
The production of two models of reduced expression of PPAR in the ovary allows
for research into the role(s) of PPAR in fertility. These models are essential to investigate
PPAR in ovarian function and fertility because a whole genome knockout of PPAR results
in embryonic death [8]. The development of the in vivo model allowed for the identification
of candidate genes that may be regulated by PPAR . Identification of these genes was the
first step in determining how PPAR affects ovarian function. Further experiments can be
performed to determine the genes that are regulated by PPAR during the reproductive cycle.
The in vitro model will also allow for investigation into how certain ligands, for example
phytoestrogens, impact ovarian biology. The in vivo model also allows for studies to be
performed on the role(s) of PPAR in fertility. These models can be used by future
researchers to further investigate the function of PPAR in ovarian biology.
These studies were the first to demonstrate that in the naturally cycling rat, PPAR
does not play a role in progesterone production or catabolism. However, a possible role for
PPAR in luteal cell survival, via activation of bcl-2, was found. Using the in vivo model
described, these studies were also able to identify candidate ovarian genes regulated by
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PPAR . The development of both in vivo and in vitro models can be used to further explore
the function(s) of PPAR in the ovary and how PPAR affects ovarian biology.
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